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Introduction
The bone marrow (BM) contains a pool of multipotent stromal cells (MSC), that 
was first described by Friedenstein and colleagues1. MSC are non-hematopoietic 
cells and are defined by the ability of plastic adherence and by their capacity to 
differentiate towards mesenchymal lineages 1-3. Friedenstein proposed the concept 
of ‘stromal stem cells’, showing the potential of MSC to give rise to bone and the 
hematopoietic environment. Later, Caplan proposed the term ‘mesenchymal stem 
cells’, but the debate on the nature, identity, function, ways of isolation and therefore 
also nomenclature of MSC in the research field continued. The International 
Society for Cellular Therapy (ISCT) made an effort to clarify the controversy in the 
field by introducing the term ‘multipotent mesenchymal stromal cells’. A hallmark 
of MSC is their capacity to differentiate in vitro towards the osteogenic, adipogenic 
and chondrogenic lineage. This multilineage differentiation capacity in vitro and in 
vivo has raised interest for their use in regenerative medicine. 
The regenerative effects of MSC may partly be a result of the secretion of factors that 
stimulate angiogenesis and suppress inflammation in a local or systemic manner. 
MSC have been shown to migrate to sites of inflammation in vivo, which might be 
relevant for their anti-inflammatory properties. The ability to suppress immune 
responses is an important feature of MSC that is currently under investigation 
aiming at the treatment of immune-related diseases, including Graft-versus-host 
disease, auto-immune diseases and inflammatory diseases like Crohn’s disease. 
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Characterization of MSC 
Source and expansion of MSC
After their first identification in BM, MSC have been isolated from a variety of 
different tissues, including adipose tissue (AT) 4, umbilical cord blood (UCB) 5, 
umbilical cord 6;7, placenta 8, synovium 9, skin 10, kidney and lung 11 and different 
fetal tissues 12;13. Kern et al. 14 compared BM-MSC, AT-MSC and UCB-MSC and 
found that MSC could be isolated from all BM and AT samples, but only from 63% of 
the UCB samples. The proliferative capacity of UCB-MSC, was higher than that of 
AT-MSC and BM-MSC. Regarding clinical application, adipose tissue has become 
attractive as an alternative source for MSC. It contains a high frequency of MSC 15 
and in addition, adipose tissue from liposuctions is at present discarded as waste 
16 and is therefore readily available. 
MSC are currently expanded in fetal calfs serum (FCS) and the use of bovine-
derived FCS has raised concerns since this might be a potential source of prions. 
Therefore, alternatives are under investigation, including human serum and human 
platelet lysate (HPL). HPL has been proven to be superior over FCS in promoting 
proliferation of MSC in culture, while the morphology, immunophenotype and 
functionality of MSC cultured in both HPL and FCS was similar 17-19.  
Phenotype of MSC
As proposed by the ISCT, that set the minimum criteria to define MSC 3, culture 
expanded MSC should express the markers CD105, CD90 and CD73 and lack 
expression of the markers CD45, CD34, CD11b, CD19 and HLA-DR. Small differences 
in immunophenotype were described for MSC isolated from different sources, e.g. 
early passage AT-MSC contain a population of  CD34 expressing cells, that is not 
detected in MSC derived from other sources 20;21. Although expression levels may 
vary, CD34 expression is maintained upon prolonged culture. The proposed surface 
markers are not related to specific functional characteristics used to define MSC. 
In search for specific subpopulations within the heterogeneous culture expanded 
MSC, the endothelial adhesion molecule CD146 (MCAM) has been identified as a 
marker to isolate MSC with a higher bone-forming capacity 22. 
The markers that are used to characterize culture expanded MSC are not 
necessarily useful for isolating MSC prospectively. Surface markers can be up- or 
downregulated in culture and little is known about the physiological features of the 
cells that give rise to the plastic adherent MSC that are expanded in culture.
Enrichment strategies were applied to prospectively isolate primary MSC from the 
resident tissue. CD271 (low affinity nerve growth factor receptor), CD105 (endoglin) 
and MSCA-1 were reported to enrich for MSC in the human bone marrow 23-25. 
Only the CD271bright population within the BM-derived mononuclear cells (MNC) 
contains colony-forming-unit-fibroblasts (CFU-F) 23;26 and CFU-F were even more 
enriched by selecting for MSCA-1+ cells 24. Further isolation on basis of CD56 
expression could differentiate between subpopulations with chondrogenic (CD56+) 
or adipogenic (CD56-) differentiation potential 24. 
Several studies showed that isolation of human perivascular cells, derived from a 
11
General Introduction
Ch
ap
te
r 1
variety of tissues using CD146 or STRO-1 expression, resulted in long-term cultures 
that exhibited a phenotype that was very similar to bone marrow-derived MSC 
and had the capacity of tri-lineage differentiation 27-29.  Moreover, using confocal 
microscopy, Crisan et al. demonstrated co-localization of the perivascular markers 
CD146+, NG2+, PDFG-β+ with the MSC markers CD44, CD90, CD73 and CD105 on 
pericytes at their native location 29. These data suggest that cells with MSC-like 
characteristics actually reside in all organs of the adult organism.
Hierarchy within the MSC population
Ex vivo expanded MSC populations exist of a heterogeneous mix of multipotent, 
bipotent and unipotent cells 30;31. For the hematopoietic system, the hierarchical 
model describing the relations between stem cells and the various progenitor 
and mature cells is well established 32. Far less is known about potential 
hierarchical relationships between MSC subpopulations. Single cells residing in 
the bone marrow of mice and humans were found that can give rise to an ectopic 
hematopoietic microenvironment 33;34. This indicates that bone marrow contains 
multipotent mesenchymal precursor cells for the different cell types that compose 
bone i.e. bone, cartilage, adipose tissue, fibroblasts and hematopoiesis-supporting 
stromal cells. Additionally, the self-renewal capacity was indicated by colony 
assays that showed that the CFU-F frequencies of secondary MSC clones were 
similar to the CFU-F frequencies of primary MSC clones 35;36. Aiming at defining 
the true stem cells within the MSC compartment of the bone marrow, Sacchetti 
showed evidence of self-renewal and multipotency of the CD45-CD146+ fraction of 
the human BM-MNC 34. Together, these data suggest that MSC populations contain 
stem cells. In the murine bone marrow, SSEA-1+ cells were defined as primitive 
stem cells that are able to contribute to different mesenchymal cell types, but also 
endodermal and hematopoietic mesodermal lineages and can give rise to SSEA-
1- mesenchymal cells 37. SSEA-1 was also found on primary human BM-MSC 38, 
but it remains unclear whether these cells were primitive stem cells similar to their 
murine counterparts. 
The existence of a common multipotent mesenchymal stem cell that can generate 
progenitors with different multilineage differentiation potentials 39, indicates a 
hierarchical model of lineage commitment. The initial reports on MSC hierarchy 
described a consecutive loss of lineages, where the adipogenic lineages diverges 
first and the osteogenic lineage is default 30;31;36;40. Subsequent studies, however, 
indicated a greater variety in bi- and unipotent clones and suggested a more 
complex model of hierarchical relations 41;42. Since no specific markers have been 
identified for the prospective isolation of multipotent stem or progenitor cells, the 
study of the hierarchy of MSC population has proven to be challenging. 
Physiological role of MSC
While MSC seem to be present in all tissues of the body, the physiological function 
of MSC in vivo is largely unknown. The role of MSC in the hematopoietic stem 
cell niche has been investigated in mice. These studies revealed that MSC are key 
players for the support of hematopoiesis 43 and as osteoprogenitors  (reviewed by 
Bianco et al. 44). Mendez-Ferrer et al. showed that MSC in the murine bone marrow 
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express nestin and that HSC were reduced in the bone marrow after depletion of 
nestin+ cells 43. In a later study, Chow et al. showed that depletion of macrophages 
resulted in the reduction in expression of HSC retention genes by nestin+ MSC. 
This indicated that the crosstalk of nestin positive stromal cells and macrophages 
in the murine hematopoietic niche seems is essential for the maintenance of the 
hematopoietic niche 45;46. 
Several studies compared MSC from patients with those from healthy controls to 
gain more insight in the physiological role of MSC. In patients suffering from severe 
aplastic anemia 47, B cell chronic lymphocytic leukemia 48 and systemic lupus 
erythematosus 49 aberrations were found in the immunoregulatory properties of 
MSC. From these comparative studies, it is however difficult to determine whether 
these aberrations in MSC are involved in the development of disease or a result 
of the progressing disease. Most studies on the immunomodulatory effects of 
MSC in vivo were performed with large numbers of cells that were expanded ex 
vivo before infusion. It is as yet unclear whether the observed immunomodulatory 
effects of MSC are biologically relevant in normal tissue homeostasis.
MSC have been isolated from placenta 8;50;51 and fetal membranes and a strong 
inhibitory effect on activated T cells was found to be exerted by fetal MSC, derived 
from amnion and decidua, as well as by maternal MSC derived from these tissues 
52. These data are compatible with the hypothesis that MSC in the placenta may 
play a role in maintaining fetal-maternal tolerance. 
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MSC and the immune system
Immunogenicity
MSC are considered as low immunogenic, in accordance with their immunophenotype 
with a low expression of HLA class II and co-stimulatory molecules 3;53;54, which 
suggests that they are not readily recognized by the immune system. However, 
murine studies showed that MSC are immunogenic in a allogeneic host and that 
they can be rejected following injection into MHC class I and class II mismatched 
mice 55-57. Moreover, several reports showed that MSC can elicit allogeneic T cell 
responses 58;59 and that they can be lysed by activated NK cells 60. 
Immunomodulation 
It has been widely shown that MSC are able to suppress the proliferation of T 
cells stimulated with allo-antigens and mitogens 53;61-66. They effectively inhibit 
dendritic cell differentiation and maturation 67-69 and the proliferation of B cells 
70-72 and IL-2 stimulated NK cells 73-77. Also the formation of regulatory T cells 
(Tregs) is promoted by MSC 74;78-80. Factors involved in these processes include 
indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), interleuking-6 (IL-6) 
galectin-1, heme oxygenase 1 (HO-1) and HLA-G5 62;64-66;69;75;81-84. Besides soluble 
factors, direct cell-cell contact is involved in the immunomodulation by MSC 84. 
The interactions of human MSC through cell-cell contact with the different cells of 
the immune system and the involved soluble factors is highlighted below. 
Figure 1. MSC interact with different cells of the immune system and a range of soluble factors is 
involved.
14
T cells
The suppression of T cell proliferation is one of the most studied immunomodulatory 
effects of MSC 53;85. Activated T cells secrete IFN-γ and TNF-α, which induce 
expression of IDO in MSC 64;86. This results in a negative feedback loop, since IDO 
catalyzes the degradation of tryptophan, which is required for T cell proliferation 87. 
The level of induced IDO expression has been correlated to the immunosuppressive 
potential 74;81;88. Addition of the IDO-inhibitor 1-MT or neutralizing antibodies against 
IFN-γ inhibited the suppressive effect of MSC on T cell proliferation and IFN-γ 
production64;76;88. In mice, MSC primarily produce inducible nitric oxide synthase 
(iNOS) rather than IDO after stimulation with IFN-γ 81;82, indicating primary effector 
molecules are different between mice and humans. 
MSC constitutively express PGE2 that suppresses the proliferation of T cells by 
several mechanisms, including the inhibition of IL-2 production and inhibition of 
intracellular calcium release (reviewed by Harris et al.89). PGE2 expression in MSC 
was upregulated upon stimulation with IFN-γ and TNF-α, secreted by activated T 
cells 74 and upon stimulation with IL-1b that was secreted by monocytes 90. This 
resulted in increased concentrations of PGE2 in co-cultures of activated PBMC with 
MSC 65;74. Addition of a PGE2 inhibitor to these co-cultures resulted in restoration 
of PBMC proliferation 65;74;90, but did not reverse the MSC-mediated inhibition of 
pro-inflammatory cytokine secretion by PBMC 65. 
Galectin-1 belongs to the family of animal lectins and has immunosuppressive and 
anti-inflammatory effects 91. MSC constitutively express and secrete galectin-1 83 
and in co-cultures of MSC with activated T cells, galectin-1 concentrations were 
increased 84. Recombinant galectin-1 showed a similar inhibitory effect as MSC 
on T cell proliferation 84 and a stable knockdown of galectin-1 in MSC resulted in 
restoration of the T cell proliferation and IFN-γ secretion, which was also observed 
after blocking galectin-1 activity in these co-cultures 83;84. 
The potent immunosuppressive enzyme HO-1 92;93  is also constitutively expressed 
by MSC, and the suppressive effect of MSC on T cell proliferation was abolished 
following inhibition of HO-1 activity 62;94. HO-1 expression was decreased in MSC 
that were co-cultured with lymphocytes in a mixed lymphocyte reaction, while 
the suppressive activity of these MSC was not diminished 94. This suggests that, 
besides HO-1, other factors are involved in MSC-mediated immunosuppression.  
HLA-G, belonging to the non-classical HLA class I molecules, has also been 
implicated in the immunomodulatory properties of MSC. The secretion of the HLA 
class I molecule HLA-G5 by MSC is induced by IL-10 and cell-cell contact with 
allostimulated T cells. Addition of neutralizing antibodies against HLA-G resulted 
in a reduced inhibition of allogeneic T cell proliferation by MSC, demonstrating the 
contribution of HLA-G5 to the immunomodulating effect of MSC 75. 
Studies that compared MSC derived from bone marrow, adipose tissue, umbilical 
cord blood or Wharton’s jelly showed that they all share the capacity to suppress 
the proliferation of stimulated T cells 7;66;95;96. Functional differences between MSC 
from different sources were also demonstrated. In a comparison of fetal and 
maternal MSC from the amnion and decidua, fetal MSC exhibited a more profound 
inhibitory effect on T cell proliferation than maternal MSC 52. 
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Regulatory T cells
The effect of MSC on the generation of Tregs has mainly been studied in vitro 
and the cytokines involved are not yet completely clear. In different experimental 
settings, MSC were able to induce an increase in the frequency of functionally 
suppressive CD4+CD25hiFoxP3+ cells when co-cultured with PBMC or T cells 79;80;97;98 
or in an allogeneic MLR 75;78;94. Other cells besides CD4 T cells seem to play a role, 
since co-cultures of MSC with whole PBMC populations resulted in Treg induction, 
while this was not observed in co-cultures with CD4+ T alone 79;80.
Several factors have been suggested to play a role in MSC-induced formation 
of Tregs. TGF-β1 was described to promote induction of Tregs in mice 99 and 
is constitutively produced by MSC 7. In co-cultures of MSC with unstimulated 
PBMC, English et al. showed that TGF-β1 and PGE2 are involved in MSC-mediated 
promotion of Treg formation 79, while others showed that blocking these two 
factors in MSC-PBMC co-cultures did not affect the MSC-mediated promotion of 
Treg formation 98. Other studies, performing co-cultures of allo-activated PBMC 
with MSC, report a role for HO-1 94 and HLA-G5 75 in the MSC-mediated induction 
of Treg formation. Despite these results, no consensus has been reached about 
the factors that are involved in the MSC-induced Treg formation. Moroever, it is 
as yet unknown whether the Tregs generated under influence of MSC are newly 
induced from CD4 effector T cells (iTregs) or that they are expanded natural 
occurring Tregs (nTregs). 
In preclinical models of allergic airway inflammation and heart transplantation, 
MSC induced the generation of Tregs in vivo 100;101. A recent study also showed 
an increased percentage of Tregs in kidney transplantation recipients after MSC 
infusion 102. 
Natural killer cells
Natural killer (NK) cells are cells of the innate immune system that are activated 
depending on the balance of stimulatory and inhibitory signals that they receive 
through their receptors. NK cells play an important role in the innate immune 
response to tumours and viruses and target cells that lack the expression of 
MHC class I 103;104. MSC escaped lysis by naïve, non-activated NK cells, but were 
susceptible to lysis by allogeneic and autologous activated NK cells 60;105-108. NK-
mediated lysis of MSC was shown to be inversely correlated to the level of HLA 
class I expression on MSC 60.  
Inversely, MSC also affect natural killer (NK) cells by inhibition of proliferation and 
of cytokine production 74-78. MSC inhibited the IL-2 induced NK proliferation, which 
was mediated by PGE2 and TGF-β1 73;76;77. Moreover, the cytolytic activity of NK 
cells was impaired by MSC, dependent on MSC-derived PGE2 and HLAG-5 73;75. 
B cells
The research on the immunosuppression by MSC has focussed predominantly on 
T cells and data on the effect of MSC on B cells are scarce 109. Studies with murine 
cells showed that MSC affect the proliferation, activation and differentiation of B 
cells stimulated with anti-CD40 and IL-4 110 or mitogens 111;112. B cell proliferation 
is inhibited by MSC through arrest in the G0/G1 phase of the cell cycle 70;72. MSC 
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also inhibit B cell differentiation by hampering the production of IgM, IgA and IgG 
70;71;111 and AT-MSC show a stronger suppression of immunoglobulin production 
than BM-MSC 113. These inhibitory effects of MSC on B cells are mediated by, 
as yet unknown, soluble factors 112. In contrast to the inhibition of activation or 
proliferation of B cells, MSC promote the survival of naïve B cells 114, a process that 
might be dependent on IL-6, that stimulated B cell proliferation 115.
Monocytes, macrophages and dendritic cells 
Monocytes are important regulators of inflammation as part of the innate immune 
response. In vitro, monocytes promote or are even required for the inhibitory effect 
of MSC on T cell activation and proliferation 59;90;116. It was reported that MSC 
promote the activation of purified T cells and only suppress T cell activation in the 
presence of monocytes 59. The interaction between MSC and monocytes results 
in skewing of monocytes towards a type of macrophage with anti-inflammatory 
properties 88;117. Monocyte-derived macrophages that were cultured with MSC 
showed characteristics of type 2 macrophages, including increased expression 
of CD206 and secretion of high levels of IL-10 and low levels of IL-12 and TNF-α 
59;116;117 . Moreover, MSC impair the allostimulatory function of monocytes 116. 
Interaction with MSC also affects the differentiation and function of dendritic 
cells (DC). In vitro, MSC inhibited CD34-derived and monocyte-derived immature 
dendritic cell (iDC) differentiation 68;69;118;119. Besides prevention of differentiation, 
MSC also impaired the antigen-presenting ability of iDC 120, the ability of mature 
DC to induce allogeneic T cell proliferation 118  and the migratory properties of DC 
121. Studies on the molecular mechanisms behind these effects of MSC revealed a 
role for PGE2 and IL-6. Inhibition of PGE2 expression reversed the MSC-mediated 
inhibition of iDC differentiation 122. Several studies proposed IL-6 as important 
factor, since IL-6 has a similar inhibitory effect on dendritic cell differentiation 
as MSC 67 and neutralising IL-6 abolished the MSC-induced inhibition of iDC 
differentiation in vitro 68;69;119. 
The involvement of monocytes/macrophages and DC in the therapeutic effect of 
MSC was studied in several animal models. Infusion of culture-expanded MSC 
impairs capacity of DC to migrate and to prime T cells in vivo 123. Also infusion 
of ex vivo modulated BM-derived macrophages, by co-culture with AT-MSC or 
AT-MSC conditioned medium, ameliorated colitis and decreased mortality in 
experimental IBD and sepsis in mice 124. In another model of sepsis, where transfer 
of MSC decreased mortality, depletion of macrophages eliminated the beneficial 
effect of MSC 125. Furthermore, infusion of MSC in mice with an experimental acute 
myocardial infarction resulted in an increased fraction of anti-inflammatory type 2 
macrophages in the blood and the heart 126. 
Overall, these studies suggest that monocytes play a decisive role in enabling MSC 
to exert their immunomodulatory activity. MSC induce the generation of regulatory 
macrophages that exert anti-inflammatory activity and this may also play a role in 
tissue repair and wound healing. 
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Immunomodulation by MSC
Animal models
The effect of both human and murine MSC administration in mice was investigated 
in several models of autoimmune diseases (reviewed by Uccelli et al. 127). MSC 
were administered in mice with experimental autoimmune encephalomyelitis (EAE) 
128;129, collagen-induced arthritis130 and experimental diabetes 131. In these models, 
infusion of MSC decreased the severity and incidence of disease, measured by 
clinical scores and inflammatory responses in the affected organs, were reduced. 
EAE-mice that were treated with MSC showed decreased demyelination and their 
T cells showed a reduced response against myelin oligodendrocyte glycoprotein 
129;132. In mice with collagen-induced arthritis, MSC treatment resulted in a reduction 
of Th1/Th17 expansion and of the production of inflammatory cytokines and in an 
increase of IL-10 production in the joints 130. Also in inflammatory diseases like 
experimental colitis, MSC alleviated the clinical symptoms. In mice with TNBS-
induced colitis, MSC treatment resulted in reduction of pro-inflammatory cytokines 
in the colon 133;134.  
In these models, the transfusion of xenogenic, allogeneic and syngeneic MSC 
produced similar effects and the beneficial effect of MSC in these animal models 
supported the use of MSC as therapy for autoimmune and inflammatory diseases. 
Another area of potential therapeutic application of MSC is the transplantation 
setting. Syngeneic 55 and xenogenic 135 MSC were shown to enhance long-term 
engraftment of allogeneic bone marrow transplants in mice, which was associated 
with tolerance to host and donor antigens 55. In solid organ transplantation, MSC 
induced Treg mediated tolerance and a synergy of MSC with immunosuppressive 
treatment was reported (reviewed by Casiraghi et al. 136). 
Co-transplantation of both allogeneic and syngeneic mouse MSC has been 
investigated for the prevention and treatment of GvHD after hematopoietic stem 
cell transplantation 137-139. Prevention or delay of GvHD development was observed 
in models where MHC-mismatched as well as MHC-haploidentical or xenogeneic 
MSC were used 140. The suppression of GvHD development by MSC was shown to 
be dependent on IFN-γ activation of MSC 139, which confirms the molecular data 
found in in vitro experiments on the immunomodulatory mechanisms of MSC. 
MSC treatment failed to prevent GvHD after disease onset, which makes it more 
challenging to use MSC to manage established GvHD. 
Safety studies 
Before starting the first studies in humans, the safety of application of xenogeneic, 
allogeneic and syngeneic MSC has been investigated in animal models. It was 
shown that murine and rhesus monkey MSC develop aneuploidies in culture and 
are prone to malignant transformation after numerous passages. Murine MSC 
showed chromosomal aberrations when expanded in culture and injection of 
murine MSC in mice resulted in sarcoma in the lungs and other organs 141-143. This 
has not been observed for human MSC, that could be culture expanded in vitro for 
up to 25 passages without signs of malignant transformation142;144. Aneuploidies, 
however, were reported in cultivated human MSC populations. This phenomenon 
18
was probably donor-dependent since multiple preparations of MSC samples from 
the same donor showed the same genetic alterations. Moreover, these cells showed 
normal senescence and no selective growth advantage or signs of malignant 
transformation were observed 145. An analysis of adverse events in clinical trials 
with MSC revealed no severe adverse events related to MSC infusion, but showed a 
significant association between MSC administration and transient fever, probably 
due to acute inflammatory reactions to preparations of MSC 146. 
Clinical studies
The use of MSC as a cellular therapy is currently explored in phase I, II and III clinical 
trials, aiming to promote of engraftment following solid organ transplantation 136 
and hematopoietic stem cell transplantation147 and to improve treatment of GvHD 
148-150, neurological diseases 151, ischemia reperfusion injury 152 and inflammatory 
diseases like Crohn’s disease 153. 
For the promotion of engraftment, MSC have been co-transplanted with 
hematopoietic stem cells or stem cell grafts. In a study by Ball et al., 14 children 
undergoing transplantation of HLA-disparate CD34+ cells were co-transplanted 
with MSC. All patients showed sustained hematopoietic engraftment, compared 
to 15% graft failure in historical controls 147. Infusion of MSC was demonstrated 
to be safe and feasible and seemed to promote the engraftment of HSC patients 
receiving an autologous HSCT 154;155.
Also for the treatment of GvHD, promising results have been reported. The first 
report was a case study of a 9-year old boy that was successfully treated with 
MSC for severe steroid resistant GvHD that occurred after transplantation of HSC 
from a haploidentical donor 150. MSC treatment resulted in a rapid healing of the 
gut epithelium. Further studies on larger patient groups with steroid refractory 
GvHD, showed that infusion of MSC resulted in resolution of GvHD in the gut, 
liver and skin and enhanced survival compared to non-responding patients 148;149. 
For these studies, MSC were derived from HLA-identical siblings, haploidentical 
donors or HLA-mismatched third party donors and no relation was found between 
the response rate and the HLA match. 
In the field of inflammatory diseases, the potential treatment of inflammatory 
bowel disease by MSC has been explored. Systemic infusion of autologous MSC 
in patients with refractory Crohn’s disease proved to be safe 156. Furthermore, local 
intrafistular injections of MSC resulted in healing of fistulising lesions in patients 
with fistulising Crohn’s disease 153. 
Biodistribution of MSC
The fate of MSC after infusion has not fully been elucidated. Intravenous 
administration of MSC resulted in entrapment of a large proportion of the infused 
cells in the lungs 157;158. In experimental colitis, only after pretreatment of MSC with 
IFN-γ, more MSC were present in the inflamed tissue compared to the surrounding 
tissues after intraperitoneal injection 133. Studies on long-term engraftment in 
human and mouse suggested that MSC do not robustly distribute in the donor 
tissues beyond the lungs and no clear evidence of sustained engraftment has 
been demonstrated 159;160. These data suggest that delivery of MSC to the site of 
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injury might not be required and that the therapeutic effect of MSC is the result of 
paracrine signalling induced by secreted factors from the MSC. With regards to the 
safety of MSC infusion, clearance of MSC from the system might limit the risks of 
ectopic tissue formation and malignant transformation.
20
Scope of this thesis
This thesis focuses on elucidating mechanisms underlying the immunomodulatory 
properties of human MSC. In addition, studies on the developmental hierarchy of 
expanded MSC are included. All studies were performed in vitro, using human MSC 
derived from bone marrow or adipose tissue. The cells were expanded according 
to the protocol that is used for the application of MSC in the clinical trials that are 
ongoing in the Leiden University Medical Center. 
Chapter 2 describes a study aiming at unravelling the clonal composition and 
hierarchical relationships within the MSC population. By studying the differentiation 
and proliferative capacity of primary and secondary MSC clones derived from bone 
marrow aspirates, we aimed to find correlates to the proliferative potential of MSC 
populations. 
Chapter 3, 4 and 5 focus on the immunomodulatory properties of MSC. These 
studies aim at selecting the most optimal source of MSC for the purpose of 
immuomodulation and at investigating the molecular mechanisms and cellular 
interactions that are involved. 
Adipose tissue has been described as an promising alternative for bone marrow 
MSC. We performed a systematic comparison of the immunomodulatory capacities 
of bone marrow-derived MSC (BM-MSC) and adipose tissue-derived MSC (AT-
MSC) derived from age-matched donors. The results of this study are described 
in chapter 3. 
In chapter 4 and 5, the immunomodulatory properties of MSC are studied and 
experiments were performed to investigate the cellular interactions and molecular 
mechanisms involved in immunomodulation by MSC. 
MSC may inhibite monocyte-derived immature dendritic cell (iDC) differentiation. 
The cytokines IL-6 and IL-10 have been determined as important factors in this 
process. In chapter 4 we describe studies on the cellular source of IL-6 and 
IL-10 and their role in the MSC-induced inhibition of monocytes-derived iDC 
differentiation.
Another important immunomodulatory effect of MSC is related to their capacity 
to induce the formation or Tregs. The mechanisms by which MSC modulate Treg 
formation are largely unclear and conflicting reports about the factors involved are 
published. In chapter 5, a novel indirect pathway, involving skewing of monocytes 
towards anti-inflammatory macrophages, is presented. 
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Abstract
Background
Multipotent stromal cells (MSC) are expanded ex vivo for various clinical 
applications. Between MSC cultures from different donors a large variation 
is observed in proliferative potential and in the capacity to differentiate into 
mesenchymal lineages.
Methods
We generated primary and secondary MSC colonies (CFU-F) from human bone 
marrow and investigated their frequency, differentiation potential and proliferation 
rate in order to find correlates to the proliferative potential of MSC cultured in bulk 
and to unravel the hierarchical relations
Results
We observed a correlation between the proliferative potential and the osteogenic 
differentiation potential, i.e. colonies with osteogenic differentiation capacity 
showed a high proliferative potential. Vice versa, fast proliferating colonies had a 
higher osteogenic differentiation capacity than slowly proliferating colonies. 
Discussion
We propose a hierarchical model in which osteogenic colonies are more primitive 
than unipotent adipogenic colonies and in which cells gradually lose their 
differentiation potential, concurrently with a loss in proliferative capacity. 
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Introduction
The bone marrow contains a pool of multipotent stromal cells (MSC), which are 
non-hematopoietic progenitor cells that possess the capacity to differentiate 
into various mesenchymal lineages 1,2 and have been shown to possess 
immunomodulatory properties 3. For their clinical application, MSC have to be 
expanded ex vivo to millions of cells. A large variation between donors exists 
with respect to the expandability of bone marrow (BM)-derived MSC populations. 
This variation cannot be explained by differences in donor age or gender, since no 
correlation was found with either proliferation capacity or CFU-F frequencies of 
MSC 4. Due to the variation in expansion potential, the required cell numbers for 
clinical use are not always reached, thus limiting their therapeutic use.
Ex vivo expanded MSC populations are composed of cells that vary in their 
differentiation capacity 5,6. The lack of markers that uniquely identify MSC in the 
resident tissue has precluded the analysis of prospectively isolated single MSC 
and instead single-cell derived MSC colonies have been studied to unravel the 
hierarchical relationships between MSC with different capacities to differentiate. 
MSC clones with multilineage differentiation potential have been identified in 
different tissues 7-9 and several hierarchical models have been proposed in 
which common multipotent stromal cells generate progeny with more restricted 
differentiation potentials 5,8-14. Studies on BM-derived MSC 5,10 showed no evidence 
for the presence of purely adipogenic colonies, while in skin-derived MSC these 
colonies were found 9. Based on these previous studies, deterministic hierarchy 
models in which the adipogenic lineage forfeits first and the chondrogenic and 
osteogenic lineage proceed together, diverging later 5,8, or models with a more 
stochastic consecutive loss of lineage potential 11 were proposed.
In this study we classified primary human BM-derived MSC colonies from expanded 
MSC populations with respect to their proliferative potential and searched for 
correlates that are associated with a high expansion potential. Furthermore, we 
aimed to further dissect the developmental hierarchy within expanded MSC at 
the earliest possible timepoint, i.e. by assessing the primary colonies and their 
progeny. By studying primary MSC colonies we formulate a model that describes 
the heterogeneity in differentiation potential that is observed in the early ex vivo 
MSC progeny. 
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Materials and methods
Generation of MSC from bone marrow
To isolate human MSC, bone marrow aspirates were harvested from the iliac crest 
of healthy individuals (age 14-69) after written informed consent, according to 
procedures that were approved by the medical ethical committee. Mononuclear 
cells (MNC) were isolated with a Ficoll-Paque density gradient (1.077 g/cm3). To 
expand MSC, the MNC were plated at 1.3 x 105/cm2 in culture medium (DMEM-
low glucose with glutamax (Invitrogen Corp., Paisley, UK) supplemented with 10% 
fetal calfs serum (FCS; Greiner Bio-one B.V. Alphen a/d Rijn, The Netherlands) 
and Penicillin/Streptomycin (P/S; Invitrogen Corp., Paisley, UK)). The cells were 
incubated at 37ºC and 5% humidified CO2 and refreshed with culture medium every 
3-4 days until confluency was reached. The MSC monolayer was detached using 
trypsin/EDTA (Invitrogen Corp., Paisley, UK) and the MSC were reseeded at 4,000/
cm2 for further expansion. 
Generation of primary MSC colonies
To generate primary separate MSC colonies (CFU-F), mononuclear cells were 
plated at lower density than was used for expansion (1.0 x 104 - 1.0 x 105 cells/
cm2 in 12-wells plates (Corning BV Life Sciences, Amsterdam, The Netherlands). 
Primary, single cell-derived MSC colonies were observed after 2-3 weeks of culture 
and only wells that contained separated colonies were used for further analysis. 
To study the difference between fast and slowly proliferating colonies, primary 
colonies of two different donors were divided into 4 groups based on their size. 
Colonies were analyzed at 100x magnification and categorized by size (‘--‘ = < 
0.25; ‘-‘ = 0.25 – 0.5, ‘+/-‘ = 0.5 – 1.0, ‘+’ = > 1.0 microscopic field). The selected 
colonies were assayed for their osteogenic differentiation potential. 
Generation of secondary colonies and expansion of clones
Primary colonies from three different MSC donors were selected for further 
analysis of the hierarchical relationships within the MSC population. Solitary 
primary colonies were identified and half of each colony was scraped off with a 
pipette tip. The scraped cells were collected in culture medium and divided in two 
equal volumes to be transferred to two separate wells of a 12-wells plate (figure 
1). One well was used for further expansion of the cells derived from the primary 
colony  to perform surface marker analysis and analysis of expansion potential 
as described below. The other well was used for the analysis of the secondary 
colonies that were generated after replating of ¼ of the cells from the primary 
colony. These secondary colonies and the remaining half of the primary colonies 
were assayed for their osteogenic and adipogenic differentiation potential.
Analysis of expansion potential
MSC were expanded in culture until 80% confluency was reached. Cells were then 
harvested with 0.25% trypsin and 1mM EDTA, counted and replated at a density 
of 4000 cells/cm2. This was repeated until the cells stopped proliferating. The 
number of population doublings was calculated with the following formula; PD = 
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logN/log2, where N is the cell number of the harvested MSC divided by the initial 
number of cells seeded. The expansion potential was defined as the total number 
of cells that could be obtained by expansion.
Osteogenic and adipogenic differentiation
The cells were cultured with osteogenic, adipogenic or osteogenic/adipogenic 
differentiation medium. 
For osteogenic differentiation, MSC were cultured in α-MEM (Invitrogen Corp., 
Paisley, UK) with L-glutamin (200nM, Invitrogen Corp., Paisley, UK), P/S and 10% 
FCS supplemented with 107 M dexamethason and 50 μg/ml Vitamin C (both from 
Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). After the first week 5 mM 
β-glycerophosphate (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) 
was added to the differentiation medium. 
For combined osteogenic/adipogenic differentiation, MSC were cultured in 
differentiation medium that consisted of α-MEM with L-glutamin, P/S and 10% 
FCS supplemented with 107 M dexamethasone, 50 μg/ml Vitamin C, insulin (10 
μg/ml), indomethacin (5μM) and IBMX (5μM) (all from Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands). After the first week 5 mM β-glycerophosphate was 
added to the differentiation medium. 
Cultures were refreshed once a week. After 21 days of differentiation, the cultures 
were stained for alkaline phosphatase activity with Fast Blue (Sigma-Aldrich 
Chemie BV, Zwijndrecht, The Netherlands) and the formation of lipid droplets was 
Figure 1. Experimental setup for analysis of primary and secondary colonies.
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visualized with Oil-red O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands). All colonies were photographed and assessed for the presence of 
ALP positive cells and/or lipid droplets. 
Flow cytometry
For analysis of surface marker expression, MSC from each expanded colony were 
trypsinized and resuspended in staining buffer (PBS/1% GPO). Primary antibodies 
were added and incubated for 30 minutes at 4ºC in the dark. Antibodies used were 
CD90-FITC, CD73-PE, CD45-FITC, CD34-PE, HLA-DR-PE, HLA-ABC-FITC, CD80-PE 
(all from BD Biosciences, San Diego, USA) and CD105-FITC (Ancell Corp., Bayport, 
MN, USA). Cells were washed with staining buffer and analyzed using a FACSCalibur 
(BD Biosciences, San Diego, CA, US). The analysis of the acquired data was done 
with FlowJo software version 7.6.1 (Tree Star Inc. Ashland, OR, USA). 
Figure 2. Heterogeneity between BM-MSC populations. 
(A) Expansion curves of BM-MSC populations. (B) CFU-F frequency of per 10 x 106 MNC. (C) 
Representative images of clones with no differentiation capacity, only adipogenic differentiation 
capacity, only osteogenic differentiation capacity and combined adipogenic/osteogenic differentiation 
capacity. (D) Frequency of differentiated/undifferentiated primary clones after culture in combined 
osteogenic/adipogenic differentiation medium. Diff = differentiated clones; Undiff = undifferentiated 
clones. 
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Results
Heterogeneity in expansion potential and clonal composition 
We analyzed CFU-F frequencies and expansion potential of MSC populations from 
two different donors and tested their primary colonies for differentiation capacity. 
Donor 1 showed a markedly higher expansion capacity than donor 2 in cultures 
that were started with 10 x 106 MNC (figure 2A). The theoretical cumulative cell 
count at day 20 of expansion was 9.4 x 107 cells for donor 1 versus 6.6 x 105 
cells for donor 2. The CFU-F frequencies for the BM aspirates, however, were 
similar. Where donor 1 contained 20 CFU-F per 1.0 x 106 MNC, donor 2 contained 
22 CFU-F per 1.0 x 106 MSC (figure 2B). 359 primary colonies of donor 1 and 91 
primary colonies of donor 2 were cultured in osteogenic/adipogenic differentiation 
medium. The cultures derived from donor 1 showed a higher frequency of clones 
with differentiation potential (osteogenic, adipogenic or both; figure 2C) compared 
to the cultures derived from donor 2 (figure 2D). These data show heterogeneity in 
the clonal composition of the primary MSC population between these two donors 
and we hypothesize that the differentiation capacity of the primary clones is 
correlated to the expansion potential of the MSC population. 
Expansion potential is positively related to osteogenic differentiation ca-
pacity
To study the possible correlation between expansion potential and differentiation 
capacity, we discriminated between large and small (see M&M) colonies, assuming 
that the large colonies represented rapidly expanding clones and the small colonies 
represented slowly expanding clones. New MSC cultures were initiated from  fresh 
BM aspirates from 2 different donors and 85 primary colonies (46 for donor 1 
and 39 for donor 2) were first categorized by size and subsequently cultured in 
osteogenic differentiation medium. Almost half (47%) of the very small colonies 
lacked osteogenic differentiation capacity, while all large (‘+’) colonies showed 
osteogenic differentiation (figure 3A). This difference in the phenotype distribution 
between small and large colonies was statistically significant (p < 0.0001). The 
progenitor cells forming small colonies exhibited a limited proliferative capacity 
and had lost the ability to differentiate into the osteogenic lineage. The progenitor 
cells that formed the large colonies exhibited a relatively high proliferative capacity 
and had retained the ability of osteogenic differentiation. These data indicate 
that MSC with a relatively high proliferative capacity maintain a high capacity for 
differentiation. 
Additionally, we  investigated the relationship between expansion potential 
and differentiation potential, starting from the other end of the equation, i.e. 
by assessing the expansion capacity ofcolonies selected on basis of their 
differentiation potential. To this end new cultures were initiated and primary 
colonies from 3 different donors were split in half and the cells in the remaining 
half were differentiated. The other half was divided in two equal parts and one 
part was used for further expansion (figure 1). The expanded cells, derived from 
primary colonies displaying osteogenic differentiation, showed a higher expansion 
potential compared to the expanded cells derived from primary colonies that were 
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only capable to differentiate along the adipogenic lineage. This resulted in a higher 
number of population doublings at day 50 of the culture (figure 3B) and a higher 
total number of cells that could be expanded from the ¼ part of the primary colony 
(figure 3C). The combined data show that colonies that possess the capacity to 
differentiate towards the osteogenic lineage have a higher expansion potential and 
suggest that these colonies contain more primitive cells than the colonies that are 
committed to the adipogenic lineage. Interestingly, some of the colonies that did 
not show either osteogenic or adipogenic differentiation displayed a proliferative 
potential comparable to the osteogenic colonies.
All expanded MSC clones, irrespective of their differentiation potential or 
proliferative capacity, showed a similar immunophenotype in accordance with the 
phenotypical definition of MSC by the International Society for Cellular Therapy 15. 
The cells were positive for the expression of CD90, CD73, HLA-ABC, CD105 and 
negative for the expression of CD45, CD34, HLA-DR and CD80. This shows that 
there is considerable functional heterogeneity within the same immunophenotype. 
Figure 3. Primary colonies with osteogenic differentiation capacity show a higher expansion potential 
than colonies with adipogenic differentiation capacity. 
(A) The frequency of osteogenic colonies correlated with the size of the colonies (chi-square test, 
P < 0.0001). (B) Number of population doublings at day 50 of expanded cells derived from primary 
colonies that showed either osteogenic or adipogenic differentiation capacity (unpaired t-test with 
Welch’s correction; *, P < .05; **, P < 0.01). (C) Expansion curves of clones with osteogenic or adipogenic 
differentiation potential.
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Differentiation potential is sequentially lost in culture
From the remaining ¼ of the primary colony, secondary colonies were derived by 
plating at low cell density. To study the hierarchical relationships within the MSC 
population, primary colonies and their secondary ‘daughter’ colonies were tested 
for osteogenic and adipogenic differentiation potential by culturing the colonies 
in osteogenic/adipogenic differentiation medium. All possible differentiation 
phenotypes were observed among the primary colonies: colonies that showed only 
osteogenic (O) differentiation, only adipogenic (A) differentiation, both osteogenic 
and adipogenic (OA) differentiation or no differentiation potential (UD). All 4 
different differentiation lineages (O, A, OA and UD) were represented in the pool of 
secondary colonies, but they had a skewed differentiation potential, i.e. secondary 
colonies, derived from OA or O primary colonies often showed differentiation 
towards only one lineage or no differentiation at all (figure 4). Furthermore, the 
differentiation of the secondary colonies did not necessarily resemble that of the 
primary colony. Primary colonies that showed only osteogenic differentiation 
could give rise to secondary colonies showing only adipogenic differentiation, 
indicating that osteogenic differentiation capacity could be disguised. However 
the opposite, a primary adipogenic colony giving rise to a osteogenic secondary 
colony, was never observed (figure 4), indicating a permanent loss of osteogenic 
differentiation capacity.
Figure 4. Differentiation capacity profile of secondary colonies is dependent on differentiation capacity 
of primary MSC colony. 
O and OA primary 
colonies produce similar 
progeny and differ from 
A primary colonies in 
their ability to produce 
secondary clones with 
A/O differentiation 
capacity. O = osteogenic; 
A = adipogenic; OA = 
osteo/adipogenic; UD = 
undifferentiated. 
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Discussion
In this study we investigated the clonal composition of BM-MSC populations 
aiming to dissect the hierarchical relationships between MSC colonies in 
expanded MSC populations. In addition, we searched for parameters that can 
be used to identify populations with high expansion potential to better meet the 
requirements with respect to cell numbers that are needed for clinical application 
of MSC. We confirm previous data showing that primary MSC populations consist 
of a mixture of colonies with multilineage, unilineage or no osteogenic/adipogenic 
differentiation potential and show that these colonies give rise to secondary 
colonies with a skewed differentiation potential. We showed that the differences in 
MSC expansion capacity between donors cannot be predicted by the frequency of 
CFU-F, but correlate with the frequency of colonies with multilineage or osteogenic 
differentiation capacity. The colonies with osteogenic differentiation capacity 
exhibited a higher proliferation rate, formed larger colonies and upon replating the 
frequency of secondary colonies with differentiation capacity was higher compared 
to colonies with only adipogenic differentiation capacity. We hypothesize that 
colonies with osteogenic differentiation capacity are more immature than colonies 
with adipogenic differentiation capacity, suggesting a developmental hierarchy. 
The MSC populations that can be expanded from different donor BM aspirates vary 
largely in cell number. These variations are influenced by the amount of blood that 
is co-aspirated, but also qualitative differences might be important. Heterogeneity 
between donors with respect to CFU-F frequency, differentiation potential of the 
colonies and proliferative potential of MSC has been described earlier 11,16. In our 
experiments we found heterogeneity in the proliferative potential that was not 
reflected in the CFU-F frequencies. Our combined data showing that colonies 
that were selected for their osteogenic capacity have a higher expansion capacity 
and, vice versa, that colonies selected for their fast proliferation have osteogenic 
differentiation capacity, indicate a relation between proliferative and differentiation 
parameters. This correlation between proliferation and differentiation confirms 
and extends previous studies pointing at this relationship 10,17-19. The positive 
correlation between differentiation capacity and expansion capacity implies 
that the number of MSC that can be expanded from a BM-MNC population is 
not only directly proportional to the plating efficiency of the cells but also highly 
dependent on qualitative parameters, such as differentiation capacity. To translate 
these findings to the clinic, a fast and effective way of identifying osteogenic, 
fast expanding colonies would increase the efficiency of the preparation of MSC 
products for therapeutic use. Identifying unique markers to prospectively isolate 
these MSC from the bone marrow would greatly progress this research field. 
As opposed to the studies by Muraglia et al. 5 and Banfi et al. 10, we detected purely 
adipogenic BM-MSC colonies. In our study, we also investigated the hierarchical 
relations in BM-MSC populations focussing on the differentiation capacities, but, 
in contrast to previous reports, we investigated the earliest primary MSC colonies 
as well as their progeny.  Based on our results we also propose a model for BM-
MSC hierarchy with sequential loss of differentiation potential. However, in our 
model, the osteogenic differentiation is default and the adipogenic differentiation 
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capacity only becomes apparent upon loss of the osteogenic differentiation 
capacity. This allows for the occurrence of secondary colonies with only adipogenic 
differentiation capacity that are derived from primary clones that show only 
osteogenic differentiation. Recently, Russell et al. also showed the emergence of 
unipotent adipogenic MSC clones from bone marrow and proposed a more complex 
hierarchical relationship, where tripotent osteogenic/adipogenic/chondrogenic 
(OAC) MSC commit via bipotent OC, OA and AC states towards unipotent O, A and 
C progenitors 11. The differences between our model for BM-MSC hierarchy and 
earlier described models are most likely due to the fact that we have analyzed the 
clonal differentiation capacity at the earliest stage i.e. without further propagation 
and subcloning of the primary MSC colonies. By using a combined osteogenic/
adipogenic differentiation, we were able to study bilineage differentiation potential 
in the very early colonies. 
Our interpretation that  osteogenic, fast proliferating MSC are more primitive than 
MSC that have lost their osteogenic differentiation capacity, fits with previously 
published gene expression data revealing that MSC populations with a high 
proliferation rate show lower expression of cell senescence genes and higher 
expression of self-renewal genes compared to clones with a low proliferation rate 
19. The positive correlation between proliferation rate and differentiation capacity 
fits in a hierarchical model where cells gradually lose their differentiation potential, 
with a concurrent loss in proliferation rate. According to this model it would be 
expected that the colonies that do not show either osteogenic or adipogenic 
differentiation expand slowly. In our data set, however, we have observed fast 
expanding clones without differentiation capacity. We currently interpret this cell 
population that is not capable of differentiation to be a mixture of MSCs that have 
lost their capacity to differentiate and other cells (e.g. fibroblasts) unequipped with 
differentiation capacity.
In conclusion, we show that a high variation in differentiation phenotypes is present 
within the primary bone marrow-derived MSC population and that the osteogenic 
differentiation potential is correlated to proliferative capacity. We propose a model 
in which colonies with osteogenic potential are more immature than colonies with 
unilineage adipogenic potential. Our results contribute to the understanding of 
the composition of the MSC pool, which might add to the optimization of MSC 
expansion for clinical application. 
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immunomodu la tor y capac i ty  than the i r 
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Abstract
AT-MSC are studied as an alternative for BM-MSC for immunomodulatory 
treatment. In this study we systematically compared the immunomodulatory 
capacities of BM-MSC and AT-MSC, derived from age-matched donors. We found 
that BM-MSC and AT-MSC share a similar immunophenotype and capacity for 
in vitro multilineage differentiation. BM-MSC and AT-MSC showed comparable 
immunomodulatory effects as they were both capable to suppress proliferation 
of stimulated PBMC and to inhibit differentiation of monocyte-derived immature 
dendritic cells (iDC). However, at equal cell numbers, the AT-MSC showed more 
potent immunomodulatory effects in both assays as compared to BM-MSC. 
Moreover, AT-MSC showed a higher level of secretion of cytokines that have been 
implicated in the immunomodulatory modes of action of MSC, such as IL-6 and 
TGF-β1. This is correlated with higher metabolic activity of AT-MSC compared to 
BM-MSC. We conclude that the immunomodulatory capacities of BM-MSC and 
AT-MSC are similar, but that differences in cytokine secretion cause AT-MSC to 
have more potent immunomodulatory effects than BM-MSC. Therefore, lower 
numbers of AT-MSC evoke the same level of immunomodulation. These data 
indicate that AT-MSC can be considered as a good alternative to BM-MSC for 
immunomodulatory therapy. 
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Introduction
Multipotent stromal cells (MSC), originally detected in bone marrow, are non-
hematopoietic progenitor cells that are defined by their ability to adhere to plastic 
surfaces and their capacity to differentiate towards different mesodermic lineages, 
including adipocytes, osteocytes and chondrocytes 1. An important characteristic 
of MSC is their immunomodulatory capacity. MSC interfere with differentiation and 
functions of multiple immunomodulatory cells. In vitro, MSC suppress the proliferation 
of T cells upon allogeneic and mitogenic stimulation 2,3, they inhibit monocyte-
derived dendritic cell differentiation and maturation 4,5 and the proliferation of B cells 
and NK-cells 6,7 and they promote the generation of regulatory T cells 8-10. Multiple 
factors have been implicated in the immunomodulatory effects of MSC, including 
indoleamine 2,3-dioxygenase (IDO), IL-6, prostaglandin E2 (PGE2) and TGF-β1 9,11-14.
The potential therapeutic application of MSC for immunomodulation has been the 
subject of many studies over the years. In experimental models, administration of 
MSC resulted in prolonged skin graft survival in baboons 15 and in prevention of 
both Graft-versus-host disesase (GvHD) 16 and the development of experimental 
autoimmune encephalomyelitis in mice 17. The use of MSC as a cellular therapy 
is currently explored in clinical trials, aiming at the promotion of engraftment 
following hematopoietic stem cell transplantation 18 and treatment of GvHD 19 and 
Crohn’s disease 20. 
Expanded bone marrow-derived MSC have been most widely used for clinical 
application, but alternative sources or subpopulations are currently under 
investigation 21,22. The frequency of MSC in bone marrow is low (0.001% - 0.01% of 
the total mononuclear cell fraction 23) and aspirating bone marrow is an invasive 
procedure. Adipose tissue is an interesting alternative to bone marrow, since 
it contains approximately a 500-fold higher frequency of MSC 24,25 and tissue 
collection is simple. Moreover, 400,000 liposuctions a year are performed in the 
US alone, where the aspirated adipose tissue is regarded as waste 26, and could 
be collected without any additional burden or risk for the donor. Adipose tissue-
derived MSC (AT-MSC) are already applied in clinical trials 21,22, but a systematic 
comparative study of bone marrow-derived MSC (BM-MSC) and AT-MSC has 
not been performed. Studies that compared MSC derived from different sources 
focused on phenotype, transcription profiling and differentiation potential 27-33. 
A few studies compared the immunomodulatory properties 30,32,34-36 and showed 
qualitative similarities between AT-MSC and BM-MSC. Quantitative analysis could 
not be performed in these studies, since different patient groups and different age 
groups were analyzed. Age is an important variable, since the composition of the 
MSC population and the functional properties of MSC change with aging 37,38. 
In this study we systematically compared the in vitro immunomodulatory capacities 
of BM-MSC and AT-MSC, derived from age-matched donors, to further define the 
advantages and disadvantages related to the use of the different tissue sources for 
MSC therapy. We show that both AT-MSC and BM-MSC are capable to suppress 
proliferation of stimulated PBMC and to inhibit differentiation of monocyte-
derived immature dendritic cells (iDC). However, AT-MSC show more potent 
immunomodulatory effects, which is related to higher levels of cytokine secretion.  
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Materials and methods
Patients
Adipose  tissue was dissected as medical waste from 9 cadaveric pancreata that 
were donated for islet transplantation in our center, according to the institutional 
guidelines regarding the use of waste material. Bone marrow from a group of 9 
age-matched donors was obtained from the iliac crest of healthy donors and from 
orthopedic patients after written informed consent, according to procedures that 
were approved by the medical ethical committee. The mean age of bone marrow 
donors was 49.2 ± 13.2 years and the mean age of adipose tissue donors was 54.2 
± 16.0 years (table 1). 
Generation of MSC from bone marrow and adipose tissue
Bone marrow-derived mononuclear cells were isolated using a Ficoll-Paque density 
gradient (1.077 g/cm3) and plated at 1.3 x 105/cm2 in proliferation medium (DMEM-
low glucose (DMEM-LG; Invitrogen Corp., Paisley, UK) supplemented with 10% fetal 
calf serum (FCS; Greiner Bio-one) and Penicillin/Streptomycin (P/S; Invitrogen Corp., 
Paisley, UK)). 
The adipose tissue was mechanically disrupted and subsequently digested using 
collagenase (2 mg/ml; Sigma) in proliferation medium. After digestion, the cell 
suspension was centrifuged to separate the adipocytes from the stromal vascular 
fraction (SVF). The SVF was filtered and the cells were plated in culture flasks in 
culture medium in a density of 1.4 x 104/cm2. 
Cultures were incubated at 37°C and 5% CO2, after 3-4 days non-adherent cells were 
removed and medium was refreshed every 3-4 days until confluency was reached. The 
MSC monolayer was detached using trypsin/EDTA (Invitrogen Corp., Paisley, UK) and 
cells were reseeded at 4,000/cm2 for further expansion. The MSC were characterized 
by immune phenotyping and used in further experiments at passage 2-5. 
Table indicates the analyses for which each donor’s cells were used. 
Table 1. Ages and origins of the MSC donors.
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Isolation of human peripheral blood mononuclear cells and monocytes
Human PBMC were isolated from buffy coats obtained from healthy donors from 
Sanquin Blood Supply (Leiden, The Netherlands) using a Ficoll-Paque density 
gradient. Monocytes were purified from the freshly prepared mononuclear cell 
fraction by MACS using CD14 microbeads (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany). Cells were separated with a MACS LS column according to 
the manufacturer’s recommendations. 
Differentiation experiments 
BM-MSC and AT-MSC were tested for their capacity to differentiate towards the 
osteogenic and adipogenic lineage. 100,00 MSC were plated in 24-wells plates 
(Corning BV Life Sciences, Amsterdam, The Netherlands) and incubated with the 
appropriate medium for induction of differentiation as stated below. All cultures 
were refreshed weekly. 
For osteogenic differentiation, MSC were cultured in α-MEM (Invitrogen Corp., 
Paisley, UK) supplemented with L-glutamin (200nM, Invitrogen Corp., Paisley, 
UK), P/S and 10% FCS, 10-7 M dexamethason and 50 μg/ml Vitamin C (both from 
Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). After the first week, 5 
mM β-glycerophosphate (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) 
was added. 
For adipogenic differentiation, MSC were incubated with medium consisting of 
α-MEM supplemented with L-glutamin, P/S and 10% FCS, 10-7 M dexamethason, 
insulin (10 μg/ml), indomethacin (5μM) and IBMX (5μM) (all from Sigma-Aldrich 
Chemie BV, Zwijndrecht, The Netherlands). 
After 3 weeks of culture, cells from all differentiation cultures were stained for 
alkaline phosphatase activity with Fast Blue (Sigma-Aldrich Chemie BV, Zwijndrecht, 
The Netherlands) and calcium deposition was determined with Alizarine Red (MP 
Biomedicals LLC, Illkirch Cedex, France) staining. Formation of lipid droplets was 
visualized using Oil-red O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands).
Suppression of PBMC proliferation
The immunosuppressive capacity of MSC was tested in a co-culture of MSC and 
PBMC. MSC were plated in graded doses in a 96-well flat-bottom plate in DMEM-
LG (Invitrogen Corp., Paisley, UK) supplemented with 10% FCS (Greiner Bio-one) 
and P/S (Invitrogen Corp., Paisley, UK). Following adherence overnight, PBMC 
(1.0 x 105/well) were added and stimulated with human T-activator CD3/CD28 
dynabeads (Invitrogen Corp., Paisley, UK) in a bead:PBMC ratio [1:5]. After 5 days 
of culture, cells were pulsed with [3H]-thymidine (0.5 µCi/well) and incubated for 
16 h at 37°C. The cultures were harvested on a glass fiber filter and thymidine 
incorporation was measured with a liquid scintillation counter (Wallac, Turku, 
Finland). Data were expressed as mean corrected counts per minute (CCPM) of 
triplicate co-cultures. Control experiments were performed, replacing MSC with 
K562 cells.
54
Inhibition of monocyte-derived immature dendritic cell differentiation
Immature dendritic cells (iDC) were generated from freshly isolated CD14+ 
monocytes by culturing 1.0 x 106 cells in 6-wells plates in RPMI (Invitrogen Corp., 
Paisley, UK) containing P/S, L-glutamin and 10% FCS supplemented with the 
growth factors IL-4 (10 ng/ml; Invitrogen Corp., Paisley, UK) and GM-CSF (5 ng/
ml; Novartis) for 6 days. To examine the effect of MSC on monocyte differentiation, 
irradiated (60 G) BM-MSC and AT-MSC were added to the culture at a MSC:monocyte 
ratio of [1:5]-[1:50]. All experiments were performed in duplicate. The experiments 
were performed in direct co-culture and in a transwell co-culture system (pore size 
0.4 μM; Corning Inc., Lowell, MA, USA). In the transwell experiments, MSC were 
plated in the lower well and monocytes were added in the transwell insert. At day 
6 the iDC were harvested from the co-culture and analyzed for expression of CD1a 
and CD14 by flow cytometry. 
Flow cytometry
After trypsinization, MSC cultures were analyzed for expression of surface markers 
using CD90-FITC, CD73-PE, CD45-FITC, CD34-PE, HLA-DR-PE, HLA-ABC-FITC, 
CD80-PE (BD Biosciences, San Diego, USA) and CD105-FITC (Ancell Corp., Bayport, 
MN, USA). The monocytes from the co-culture experiments were collected at day 
6 and analyzed for surface marker expression using CD1a-FITC and CD14-PE (BD 
Biosciences, San Diego, CA, USA). Cells were incubated with fluorescent-labeled 
antibodies 30 minutes at 4°C in the dark. After washing with PBS/1% albumin they 
were analyzed using a FACSCanto II (BD Biosciences, San Diego, CA, US). The 
analysis of the acquired data was done with FlowJo software version 7.6.1 (Tree 
Star Inc. Ashland, OR, USA). 
Cytokine assay
To determine cytokine concentrations in the supernatants of PBMC proliferation 
cultures and the monocyte cultures, cell-free supernatant was collected at day 5 
and 6 respectively and stored at -20°C until use. Cytokine concentrations were 
measured using the Bio-Plex Pro Human Cytokine Th1/Th2 panel (Bio-Rad 
laboratories, Inc, Hercules, CA, USA). To analyze constitutive cytokine secretion, 
BM-MSC and AT-MSC cells were plated at confluent cell concentrations (2.0 x 
105 cells in a 12-wells plate) and cultured without medium replacement. At day 
7, cell-free culture supernatant was collected and stored at -20°C and MSC were 
harvested and counted. Cytokine concentrations were measured using the Bio-
Plex Pro Human Cytokine 27-plex panel (Bio-Rad laboratories, Inc, Hercules, CA, 
USA) or sandwich ELISA (BD Biosciences, San Diego, CA, USA). 
MTT assay
In a 96-wells plate, 2.0 x 104 MSC were plated in DMEM-LG (Invitrogen Corp., 
Paisley, UK) supplemented with 10% FCS (Greiner Bio-one) and P/S (Invitrogen 
Corp., Paisley, UK). After overnight adherence, the medium was replaced with 
100 μl colorless IMDM medium (Invitrogen Corp., Paisley, UK) supplemented with 
P/S and 10% FCS. For measurement of the metabolic activity 10 μl of 12mM MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) stock solution 
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(Life Technologies, Grand Island, NY, USA) was added to each well and incubated 
for 4 hours at 37°C. Then 75 μl of the medium was removed and 100 μl DMSO was 
added and incubated for 10 minutes at 37°C. Absorbance was read at 540 nm. 
IFN-γ stimulation of MSC
To analyse IDO upregulation induced by IFN-γ, MSC were plated at a concentration 
of 2.0 x 105 cells per well in a 12-wells plate and IFN-γ was added to the culture 
medium (500 U/ml; Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). At 
timepoints 0, 4, 8 and 24 hours, RNA was extracted and cell-free supernatant was 
collected and stored for further analysis at -20°C. 
Gene expression analysis
RNA was extracted from MSC using the RNeasy micro kit from Qiagen. cDNA 
was synthesized with Superscript III RT (Invitrogen, GmbH, Hilden Germany). RT-
qPCR analyses were performed on a StepOnePlus real-time PCR system (Applied 
Biosystems, Foster city, CA, USA) using SYBR Green reagent (Roche Diagnostics, 
Almere, The Netherlands). The following primer sets were used:
Gene Forward Reverse
IDO 5’-CCTGAGGAGCTACCATCTGC-3’ 5’-TCAGTGCCTCCAGTTCCTTT-3’
IL-6 5’-TTCAATGAGGAGACTTGCCTG-3’ 5’-ACAACAACAATCTGAGGTGCC-3’
β-actin 5’-AGGCATCCTCACCCTGAAGTA-3’ 5’- CACACGCAGCTCATTGTAGA-3’
All RT-qPCR Data were normalized to β-actin expression and the data were 
analyzed using the delta-Ct method. 
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Results
BM-MSC and AT-MSC have similar phenotype and differentiation capacity 
Immunophenotypic analysis of BM-MSC and AT-MSC showed a similar surface 
marker expression profile (figure 1A-C). This profile is in accordance with the 
phenotypical definition of  MSC by the International Society for Cellular Therapy 
1, with the exception of CD34, that was expressed only on a fraction of AT-MSC 
(27.4% ± 9.8%, n = 4) (figure 1C). 
Both BM-MSC and AT-MSC were able to differentiate towards the osteogenic and 
the adipogenic lineage (figure 2). No differentiation was observed for MSC that 
were cultured in medium only.
Representative histograms of BM-MSC (A) and AT-MSC (B) FACS analysis. All AT-MSC donors show a 
CD34+ population. Grey histograms are isotype control. (C) Cumulative data of FACS analysis of BM-
MSC and AT-MSC for several surface markers. The expression of CD34 is significantly higher on AT-
MSC compared to BM-MSC (data are means from 4 BM-MSC and 5 AT-MSC donors; statistical analysis 
was performed using a 2-way ANOVA; *, p < 0.05; **, p < 0.01; ***, p < 0.001).
Figure 1. BM-MSC and AT-MSC show the same immunophenotype, except for CD34 expression.
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AT-MSC are more potent in their suppression of PBMC proliferation than 
BM-MSC
Functional suppression
Both BM-MSC and AT-MSC were able to suppress the proliferation of PBMC in a 
dose dependent fashion (figure 3A). However, addition of equal numbers of AT-
MSC resulted in significantly higher levels of suppression of PBMC proliferation 
compared to BM-MSC (figure 3A). Approximately 3 times more BM-MSC were 
needed to obtain the suppressive effect that was observed with AT-MSC. At a ratio 
MSC:PBMC of [1:3], both BM-MSC and AT-MSC showed almost complete inhibition 
of PBMC proliferation. Control experiments, replacing MSC with K562 cells, showed 
that the effect on proliferation was not due to cell crowding or exhaustion of the 
culture medium (data not shown). 
Cytokine production
In the presence of increasing amounts of both BM-MSC and AT-MSC, the 
concentrations of the pro-inflammatory cytokines IL-12, TNF-α and IFN-γ, in the 
culture supernatants of PBMC-MSC co-culture, decreased in a dose-dependent 
fashion (figure 3B). At a ratio MSC:PBMC of [1:30], the IFN-γ concentrations in the 
culture supernatant were significantly lower (p<0.01) in the presence of AT-MSC 
compared to BM-MSC (figure 3B).
The upregulation of IDO expression in MSC following IFN-γ stimulation is 
Confluent cultures of BM-MSC (A,B,C) and AT-MSC (D,E,F) were maintained in osteogenic differentiation 
medium (A,D), adipogenic differentiation medium (B,E) or control medium (C,F). After three weeks of 
culture in differentiation medium, both BM-MSC and AT-MSC were positive for alkaline phosphatase 
activity (A,D) and lipid droplets were formed (B,E). Control cultures in proliferation medium did not 
show alkaline phosphatase activity or the formation of lipid droplets. MSC populations from 6 BM-MSC 
donors and from 8 AT-MSC donors were tested for their differentiation capacity, representative pictures 
are shown for BM-MSC and AT-MSC. Bar = 50um.
Figure 2. BM-MSC and AT-MSC both differentiated towards the osteogenic and adipogenic lineage.
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regarded as an important mechanism for the MSC-induced suppression of PBMC 
proliferation. Therefore, we investigated the level and speed of induction of IDO 
expression in response to IFN-γ stimulation in BM-MSC and AT-MSC. Following 
IFN-γ stimulation, expression of IDO mRNA was induced in both BM-MSC and 
AT-MSC populations. Between 4 and 24 hr after IFN-γ stimulation, the average 
IDO expression in AT-MSC was higher than in BM-MSC. However, due to the high 
variation, the difference did not reach statistical significance. At 8 hours, the 
(A) MSC suppress PBMC proliferation in a dose dependent fashion. AT-MSC show a significant stronger 
suppression of proliferation at MSC:PBMC ratios [1:100], [1:32] , and [1:10] (2 separate experiments, n = 
9 for AT-MSC, n = 8 for BM-MSC). (B) From one experiment, culture supernatants of PBMC proliferation 
in the presence and absence of MSC were assayed for cytokine concentrations at day 5 of co-culture 
(n = 3 for both groups). Statistical analysis was performed using the student’s t-test (data are mean ± 
SEM; * = compared to control; *, p < 0.05; **, p < 0.01; ***, p < 0.001; # = AT-MSC compared to BM-MSC; 
#, p < 0.05, ##, p < 0.01)). (C) After IFN-γ stimulation of MSC, both BM-MSC and AT-MSC show IDO 
mRNA upregulation, with an optimum at 8 hours. IDO mRNA expression is relative to β-actin mRNA 
expression. Statistical analysis was performed using a student’s t-test (n = 3 for both groups).
Figure 3. AT-MSC are more potent in suppressing PBMC proliferation compared to BM-MSC.
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highest expression levels of IDO were observed for both AT-MSC and BM-MSC 
(figure 3C). 
AT-MSC are more potent in inhibiting dendritic cell formation than BM-MSC
BM-MSC and AT-MSC were further tested for their capacity to inhibit the 
differentiation of CD1a-CD14+ monocytes towards CD1a+CD14- immature dendritic 
cells (iDC). Both AT-MSC and BM-MSC exhibited this inhibitory effect at a 
MSC:mono ratio of [1:10] (figure 4A,B). Also in this immunomodulation assay, a 
clear difference in the dose-response relation was observed, in favor of AT-MSC 
(figure 4C). At a MSC:monocyte ratio of [1:20], AT-MSC showed the same level of 
inhibition as BM-MSC showed at a ratio of [1:5].
Addition of BM-MSC and AT-MSC increased the concentrations of the anti-
inflammatory cytokine IL-10 in supernatants of cultures from monocytes that 
(A) Representative dotplots of monocyte differentiation towards iDC in the absence and presence of BM-
MSC and AT-MSC (MSC:monocyte ratio of [1:10]). (B) Cumulative data of CD1a and CD14 expression 
on differentiated monocytes. Data are means from 3 different BM-MSC and 3 different AT-MSC (MSC: 
monocyte ratio of [1:10]), statistical analysis was performed using the student’s t-test (*, p < 0.05; **, p < 
0.01; ***, p < 0.001). (C) Dose-response curves of the percentage of CD14+ cells in the presence of BM-MSC 
or AT-MSC. (D) IL-10 concentrations in culture supernatants from day 6 of the monocyte differentiation in 
the presence of BM-MSC and AT-MSC are increased compared to the differentiation without MSC. Data are 
means from 3 different experiments with 6 different BM-MSC and 3 different AT-MSC (MSC:monocyte ratio 
of [1:10]), statistical analysis was performed using a student’s t-test (* = compared to -MSC; *, p < 0.05; **, 
p < 0.01; ***, p < 0.001; # = BM-MSC compared to AT-MSC; #, p < 0.05; ##, p < 0.01).
Figure 4. AT-MSC are more potent inhibitors of monocyte differentiation than BM-MSC.
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were differentiated towards iDC (figure 4D). Again, addition of AT-MSC resulted in 
a significantly higher concentrations of IL-10 than addition of BM-MSC (1481.0 ± 
118.8 pg/ml versus 961.8 ± 159.5 pg/ml, n = 3, p < 0.01).
AT-MSC secrete higher concentrations of cytokines compared to BM-MSC
To investigate whether the difference in potency in the various immunomodulatory 
assays could be explained by a generally increased cytokine secretion by AT-MSC 
compared to BM-MSC, cytokine profiling was performed in culture supernatant 
of unstimulated MSC. After 7 days of culture, no differences were observed in the 
number of cells between AT-MSC and BM-MSC cultures. Culture supernatants 
from AT-MSC cultures generally contained higher concentrations of cytokines 
than culture supernatants from BM-MSC and the reverse phenomenon was never 
observed. The differences were significant for the cytokines IL-6, IL-8, IL-12, 
Eotaxin and TGF-β1 (figure 5A). The largest differences were found for IL-6 and 
TGF-β1. For IL-6, this difference in cytokine concentrations was confirmed at the 
transcriptional level (figure 5B).
We hypothesized that the generally enhanced levels of multiple cytokines in AT-
MSC are the result of a higher metabolic activity in AT-MSC. To test this hypothesis, 
we directly analyzed the metabolic activity of BM-MSC and AT-MSC using an MTT 
assay. Indeed the AT-MSC showed a higher average metabolic activity compared 
to BM-MSC, however this observation reached only borderline significance (P = 
0.06) (figure 5C). 
(A) Cytokine concentrations 
measured in culture supernatant 
were higher for AT-MSC compared 
to BM-MSC. A representative 
experiment is shown from 3 separate 
experiments. (n = 4 for both groups; 
IL-6 values represent 1.0x10-1 
of the measured concentrations, 
represented IL-12 values are 10x 
the measured concentrations). (B) 
IL-6 mRNA expression was also 
increased in AT-MSC compared to 
BM-MSC (n = 3 for both groups). (C) 
AT-MSC show a slightly enhanced 
MTT activity; MTT activity AT-MSC 
is relative to BM-MSC (n = 3 for 
both groups). Data are means ± 
SEM from 3 different experiments, 
statistical analysis was performed 
using a student’s t-test  (*, p < 0.05; 
**, p < 0.01; ***, p < 0.001).
Figure 5. AT-MSC secrete higher levels of cytokines compared to BM-MSC.
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Discussion
AT-MSC are considered as an alternative to BM-MSC for clinical application 16,30,39. 
In this study we performed an in vitro systematic comparison of BM-MSC and 
AT-MSC from age-matched donors. We found a similar phenotype and capacity 
for multilineage in vitro differentiation towards the osteogenic and adipogenic 
lineages. We observed that both BM-MSC and AT-MSC exhibit the capacity 
to inhibit PBMC proliferation as well as monocyte differentiation towards iDC. 
However, the dose-response curve for AT-MSC was clearly different than for BM-
MSC. To acquire the same level of suppression, a lower number of AT-MSC were 
required than BM-MSC. Furthermore, AT-MSC secreted higher levels of cytokines 
than BM-MSC, which corresponded to a higher metabolic activity. 
The expression of surface marker CD34 on a subpopulation of the AT-MSC has 
previously been described. This expression decreases during culture expansion 
40-42, explaining the observed variation. The relevance of CD34 expression on AT-
MSC is currently unclear. CD34+/CD31- cells have been detected at perivascular 
locations in adipose tissue 43. These cells can  differentiate in vitro towards 
endothelial cells 44, which suggests that they might play role in vasculogenesis. 
Such preferred role for these CD34+/CD31- cells is not supported by the findings 
of Suga et al., who showed similar capabilities for capillary-network formation for 
CD34+ and CD34- AT-MSC45. 
Several studies have compared BM-MSC and AT-MSC, but mostly small groups of 
donors and different patient groups and age groups were investigated. The reports 
described that AT-MSC and BM-MSC both exhibit the capacity to inhibit PBMC 
proliferation, but indicated no differences between the MSC populations 30,32,34-36. 
We also show that both populations are able to inhibit PBMC proliferation, but with 
a different dose-response curve. Others used MSC concentrations at the plateau 
phase of the dose-response curve and MSC from different patient groups and age. 
Therefore they did not find differences in potency between AT-MSC and BM-MSC. 
We show that differences are only found at concentrations in the linear phase of 
the dose-response curve. 
The more potent suppression of PBMC proliferation by AT-MSC than by BM-MSC 
was also reflected in the cytokine concentrations measured in the co-culture 
supernatants of the PBMC-MSC co-cultures. Our data suggest that both BM-MSC 
and AT-MSC induce a shift from a Th1 towards a Th2 response, since the pro-
inflammatory cytokines IL-12, TNFα and IFN-γ concentrations were significantly 
reduced in culture supernatants of PBMC cultured in the presence of either type 
of MSC. This effect was stronger in the presence of AT-MSC than in the presence 
of BM-MSC and for IFN-γ this difference between AT-MSC and BM-MSC became 
statistically significant. 
IFN-γ has also been implicated in the initiation of the immunosuppressive function 
of MSC. Activation of MSC by IFN-γ is involved in the inhibitory effect of MSC 
on T cell proliferation through induction of expression of IDO, an enzyme that 
catabolizes tryptophan 13. The level of induced IDO expression differs between 
MSC populations and has been correlated to their immunosuppressive potential 
46. We found that, in response to IFN-γ, IDO expression is induced to higher levels 
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in AT-MSC than in BM-MSC. The more potent inhibitory effect of AT-MSC on PBMC 
proliferation can be explained by this stronger response to IFN-γ, i.e. the IFN-γ that 
is produced by the activated PBMC causes a stronger or more adequate response 
of the AT-MSC resulting in stronger inhibition of the PBMC proliferation, finally 
resulting in lower concentrations of IFN-γ and other pro-inflammatory cytokines. 
We have shown in vitro that MSC  inhibit monocyte differentiation towards iDC and 
rather skew monocytes towards a tolerogenic cell type, with increased secretion 
of the immunomodulatory cytokine IL-10  47. In our monocyte-MSC co-cultures, 
the secretion of the immunomodulatory cytokine IL-10 was more pronounced 
in the presence of AT-MSC than in the presence of BM-MSC. This indicates that 
the monocytes have become more tolerogenic in the presence of AT-MSC. Since 
activated monocytes have been shown to increase their IL-10 expression upon 
IL-10 exposure, creating a positive feedback loop 48, this difference in effect of AT- 
versus BM-MSC might even be further enhanced.
Compared to BM-MSC, AT-MSC constitutively secrete higher levels of multiple 
cytokines that have been implicated in MSC-mediated immunomodulation, such 
as IL-6 and TGF- β1 5,11,49,50. We have shown that IL-6 is a key factor for the MSC-
induced inhibition of monocyte differentiation towards iDC and the induction of IL-
10 secretion by monocytes 47. The higher IL-6 secretion by AT-MSC can therefore 
explain the more pronounced inhibition of iDC generation and the increased IL-
10 protein concentrations that were observed in the monocyte cultures in the 
presence of AT-MSC. TGF-β1 has been implicated in the generation of regulatory 
T cells by MSC 11,14. Therefore, we hypothesize that the observed higher TGF-β1 
production by AT-MSC may also be associated with an increased ability to induce 
regulatory T cells.
The overall explanation for the observed functional superiority of AT-MSC may 
be the its higher metabolic activity, resulting in production of higher levels of 
cytokines that are involved in the immunosuppressive mechanisms of MSC. It is 
therefore conceivable that this also holds true for other factors that are involved in 
immunomodulation by MSC, like PGE2 30,51, galectin-1 52,53 and HLA-G5 54.
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Conclusion
Our data show that BM-MSC and AT-MSC share a similar immunophenotype and 
capacity for in vitro multilineage differentiation. Also functionally, BM-MSC and AT-
MSC show similar immunomodulatory effects, but with a different dose-response 
curve, in favor of AT-MSC. We show that the differences in immunomodulatory 
properties between BM-MSC and AT-MSC are primarily due to the quantitative 
aspects of the suppression, which are likely related to their respective metabolic 
activity. These data support the notion that AT-MSC could be a promising 
alternative for BM-MSC for future clinical immunomodulatory applications. 
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Abstract 
Background
Multipotent stromal cells exhibit immunomodulatory capacities and have been 
applied in transplantation and autoimmune diseases. One of the effects of MSC 
involves the inhibition of dendritic cell differentiation. Since IL-6 and IL-10 are 
known to play a role in inhibiting immature dendritic cell differentiation, we 
hypothesized that these cytokines also may mediate the inhibitory effect of human 
MSC in immature dendritic cell differentiation.
Design and Methods
Monocytes were cultured with IL-4 and GM-CSF in the presence or absence of 
culture-expanded bone marrow-derived multipotent stromal cells. Neutralization 
and cytokine-depletion strategies were applied to reveal the cellular source and 
effect of IL-6 and IL-10. 
Results
Addition of multipotent stromal cells to monocyte cultures significantly reduced the 
generation of immature dendritic cells (CD14-CD1a+) and resulted in the generation 
of CD14+CD1a- cells that displayed a significantly reduced immunostimulatory 
effect. We found that culture supernatants of co-cultures of multipotent stromal 
cells and monocytes contained higher concentrations of IL-6 and IL-10. multipotent 
stromal cells produce IL-6 and neutralizing this IL-6 reversed the inhibitory effect 
of multipotent stromal cells. IL-10 was not produced by multipotent stromal 
cells, but exclusively by monocytes after exposure to multipotent stromal cells-
produced IL-6. 
Conclusions
By the constitutive production of IL-6, multipotent stromal cells prevent the 
differentiation of monocytes towards antigen-presenting immunogenic cells and 
skew differentiation towards an anti-inflammatory IL-10 producing cell type.
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Introduction
Multipotent stromal cells (MSC) are non-hematopoietic progenitor cells that have 
been identified in different tissues and are capable of differentiation towards 
adipogenic, osteogenic and chondrogenic lineages. Importantly, MSC display 
immunoregulatory properties. These properties have been the subject of many 
studies over the years and make MSC interesting candidates for further clinical 
application.
In several experimental disease models, MSC have been shown to modulate 
immune responses in vivo. Administration of MSC has been shown to prevent 
Graft-versus-host disease (GvHD) 1, the development of experimental autoimmune 
encephalomyelitis in mice 2 and results in prolonged skin graft survival in baboons 
3. The use of MSC as a cellular therapy is currently explored in clinical trials, 
including treatment of GvHD 4, promotion of engraftment following hematopoietic 
stem cell transplantation 5 and treatment of Crohn’s disease 6. 
The mechanisms underlying the immune suppression by MSC are still unclear. 
It has been widely shown that MSC suppress the proliferation of T cells upon 
allogeneic or mitogenic stimulation 7,8. Soluble factors proposed to be involved in 
this effect include indoleamine 2,3-dioxygenase, prostaglandin E2, TGF-β1, IL-6 
and heme oxygenase 1 9-13. MSC also inhibit the proliferation of B cells and IL-2 
stimulated NK cells 14,15 and  have been described to promote the formation of 
regulatory T cells (Tregs) 16-18.
MSC can also modulate immune responses through inhibition of monocyte-
derived immature dendritic cell (iDC) differentiation 19,20. Monocyte differentiation 
towards iDC can be inhibited by IL-6 and IL-10 21,22 and several studies suggested 
that IL-6 may play a role in the inhibitory effect of MSC on the differentiation of 
monocyte to dendritic cells 19,20. These data are however derived from in vitro co-
culture experiments of MSC and monocytes, where the cellular source of cytokine 
production has not been identified. Therefore, the specific role of these cytokines 
for  this inhibiting MSC functionality is still unclear.
In this study, we further investigated the mechanism of inhibition by MSC during 
the differentiation of monocyte towards iDC and focussed on the exact source 
of the cytokines involved. To this end we performed co-culture, transwell and 
supernatant-supplemented experiments of monocytes and MSC and applied 
neutralization and depletion strategies to reveal the cellular interactions that are 
crucial for the immunomodulating effect of MSC on monocyte differentiation. We 
found that MSC inhibit monocyte-derived iDC differentiation and skew monocytes 
towards a cell type with a low allostimulatory capacity. We show that this process 
is dependent on the IL-6 produced by MSC, that subsequently induces monocyte-
derived cells to produce IL-10, a cytokine involved in immune suppression and 
that is not produced by MSC. 
In conclusion, our results reveal a potential powerful role for MSC that, through 
their production of IL-6, program monocytes to become anti-inflammatory cells 
that prevent or reduce tissue damage and modulate the immune response.  
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Generation of human MSC 
After obtaining informed consent, adult bone marrow was harvested from healthy 
donors or from orthopedic patients. Mononuclear cells were isolated using a 
Ficoll-Paque density gradient (1.077 g/cm3) and were plated at 1.3 x 105/cm2 in 
DMEM-low glucose (Invitrogen Corp., Paisley, UK) supplemented with 10% fetal calf 
serum (FCS; Greiner Bio-one) and Penicillin/Streptomycin (P/S; Invitrogen Corp., 
Paisley, UK). After 3-4 days the non-adherent cells were removed and medium was 
refreshed every 3-4 days until the cells reached confluency. The MSC monolayer 
was detached using trypsin/EDTA (Invitrogen Corp., Paisley, UK) and reseeded at 
4,000 cells/cm2 for expansion. The MSC were characterized by FACS analysis and 
used in the co-culture experiments at passage 2-5.
Isolation of monocytes
Human PBMC from healthy donors were isolated from buffy coats obtained 
from Sanquin Blood Supply using a Ficoll-Paque density gradient (1.077 g/cm3). 
From the freshly prepared mononuclear cell fraction, CD14 positive monocytes 
were purified by MACS using CD14 microbeads (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany). Cells were separated with a MACS LS column according to 
the manufacturer’s recommendations. 
Differentiation of monocytes
Freshly isolated monocytes (CD14+) were cultured at a concentration of 1.0 
x 106 cells/well  in 6-wells plates (Corning BV Life Sciences, Amsterdam, The 
Netherlands) in RPMI (Invitrogen Corp., Paisley, UK) containing P/S, L-glutamin 
(Invitrogen Corp., Paisley, UK) and 10% FCS supplemented with the growth factors 
IL-4 (10 ng/ml) and GM-CSF (5 ng/ml) (both from Invitrogen Corp., Paisley, UK) for 
6 days, resulting in the generation of iDC (CD14-/CD1a+) . To examine the effect of 
MSC on monocyte differentiation, irradiated MSC (60Gy) were added to the culture 
at a MSC:monocyte ratio of 1:10 as was described before (23, 24). The co-culture 
experiments were performed in direct cell-cell contact and in a transwell co-
culture system (pore size 0.4 μM; Corning Inc., Lowell, MA, USA). In the transwell 
experiments, MSC were plated in the lower well and monocytes were added to the 
transwell insert. All experiments were performed in duplicate. In some experiments 
IL-10 (20 ng/ml), IL-6 (100 ng/ml), anti-IL-10 (2–20 μg/ml) or anti-IL-6 (2.5 μg/
ml) (all from R&D systems Europe Ltd., Abingdon, UK) was added. The involvement 
of secreted factors was further assessed by addition of MSC conditioned medium 
(MSC-CM) to the monocyte differentiation culture. Conditioned medium was 
generated by collecting cell-free culture supernatant from MSC alone (MSC-CM), 
MSC cultured with growth factors (MSC+GF CM) and from the monocyte-MSC co-
cultures (MSC+mono CM). In some experiments, IL-6 
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was depleted from the MSC-CM using the μMACS Streptavidin kit (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). Cell free MSC supernatant was incubated 
with biotinylated anti-IL-6 (2 μg/ml, BD Biosciences, San Diego, CA, USA) and 
μMACS Streptavidin microbeads. IL-6 was depleted from the medium using a 
μMACS column according to the manufacturer’s recommendations. MSC-CM was 
used in the monocyte differentiation in a 2:1 ratio with fresh medium. 
FACS analysis 
At day 6 the monocyte-derived cell population was harvested from cultures and 
analyzed for surface marker expression using CD1a-FITC and CD14-PE (BD 
Biosciences, San Diego, CA, USA) by flow cytometry. MSC were trypsinized and 
analyzed for expression of surface markers using CD90-FITC, CD73-PE, CD45-FITC, 
CD34-PE, HLA-DR-PE, HLA-ABC-FITC, CD80-PE (BD Biosciences, San Diego, USA) 
and CD105-FITC (Ancell Corp., Bayport, MN, USA). For surface staining, cells were 
collected and primary antibodies were added and incubated for 30 minutes at 4°C 
in the dark. Cells were washed with PBS/1%GPO and analyzed using a FACSCanto 
II (BD Biosciences, San Diego, CA, US). The analysis of the acquired data was done 
with FlowJo software version 7.6.1 (Tree Star Inc. Ashland, OR, USA). Statistical 
analysis was performed using the Student t test. 
Analysis of cytokines
Cytokine concentrations were measured in cell-free supernatants collected at 
day 6 from cultures of monocytes with or without MSC. To distinguish between 
cytokines produced by MSC or monocytes, the cells from the transwell co-cultures 
were separated at day 6 and cultured further in fresh medium for an additional
2 days. IL-6 protein concentrations were determined in supernatants of these 
cultures. 
We also measured the of cytokine concentrations in supernatants of unstimulated 
MSC and MSC cultures containing IL-4 and GM-CSF. Culture supernatants were 
stored at -20°C until use. Cytokine concentrations were measured using the Bio-
Plex Pro Human Cytokine assay (Bio-Rad laboratories, Inc, Hercules, CA, USA) 
or by sandwich ELISA (BD Biosciences, San Diego, CA, USA). Statistical analysis 
was performed using a Student t–test and a p<0.05 was considered statistically 
significant. 
Gene expression
Total RNA was extracted from MSC and monocyte populations using the RNeasy 
micro kit (Qiagen GmbH, Hilden, Germany). cDNA was synthesized with Superscript 
III RT (Invitrogen Corp., Carlsbad, CA, USA). Q-PCR analyses were performed on 
a StepOnePlus real-time PCR system (Applied Biosystems, Foster city, CA, USA) 
using Sybr Green. The following primer sets were used:
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Gene Forward Reverse
IL-6 5’-TTCAATGAGGAGACTTGCCTG-3’ 5’-ACAACAACAATCTGAGGTGCC-3’
IL-10 5’-CCGAGATGCCTTCAGCAGAG-3’ 5’-GGTCTTGGTTCTCAGCTTGG-3’
β-actin 5’-AGGCATCCTCACCCTGAAGTA-3’ 5’- CACACGCAGCTCATTGTAGA-3’
All data were normalized using β-actin as a reference gene. 
Allogeneic mixed lymphocyte reaction assay
Monocytes cultured for 6 days in the presence or absence of MSC in a transwell 
co-culture, were tested for their ability to stimulate the proliferation of allogeneic 
T cells. Allogeneic CD4+CD25- T cells were isolated from PBMC by MACS (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany) using the CD4+CD25+ regulatory T cell 
isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). CD4 T cells 
were isolated from PBMC using a cocktail of biotin-labeled antibodies against 
CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRγ/δ and CD235a and anti-biotin 
microbeads followed by separation of CD4+CD25- and CD4+CD25+ T cells with CD25 
microbeads. The CD4+CD25- T cells were stimulated with iDC or the monocyte-
derived cells from the monocyte-MSC co-culture (MDC) at various ratios. After 
four days incubation, cells were pulsed overnight with 0.5μCi of [3H]-thymidine to 
determine T cell proliferation. Thymidine incorporation was expressed as mean 
corrected counts per minute (CCPM). 
Statistical analysis
All data represent the average and standard deviation of multiple MSC donors. 
Unless otherwise specified, statistical analysis was tested by the Student’s t test 
for two groups and by a two-way ANOVA with a Bonferroni posttest for comparison 
of 3 groups using Prism5 software (GraphPad Software, Inc., CA, USA). 
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Results
MSC skew the differentiation of monocytes to the formation of CD14+ cell 
with low allostimulatory capacity
Monocytes (purity after MACS isolation was more than 90% CD14+ cells) cultured 
in the presence of IL-4 and GM-CSF differentiated into CD1a+CD14- immature 
dendritic cells (iDC). Following addition of MSC to these cultures, monocyte 
differentiation towards iDC was inhibited (Figure 1A-B). In the presence of MSC, a 
significantly lower fraction of monocytes acquired CD1a (15.1 ± 7.4% versus 70.6 ± 
8.8%, p = 0.002, n = 7) and a significantly lower fraction lost CD14 expression (52.2 
± 8.1 % versus 99.5 ± 0.1 %, p = 0.001, n = 7) (Figure 1B). 
The MSC were analyzed for expression of surface markers before and after co-
culture with monocytes. MSC expressed HLA-class I, CD73, CD105 and CD90 and 
did not show expression of HLA-class II, CD31, CD45 , CD80 and CD34. No changes 
were observed after co-culture with monocytes. 
The monocyte-derived populations, formed in the absence or presence of MSC 
in transwell co-cultures, were functionally tested for their ability to induce 
proliferation of allogeneic T cells (Figure 1C). iDC effectively induced proliferation 
of allogeneic CD4+CD25- T cells. The monocyte-derived population that was 
generated in the presence of MSC, showed a significantly reduced allostimulatory 
capacity compared to the iDC (corrected counts per minute (CCPM), *, p<0.05; **, 
p< 0.01; ***, p<0.001, n = 3). 
(A) Representative FACS plots of the differentiation of CD14+ monocytes towards iDC with or without 
MSC in a direct co-culture. (B) Cumulative data of 7 independent experiments with 6 different MSC 
donors and 7 different monocyte donors (data are mean ± SEM significance is relative to –MSC 
*p<0.05). (C) Corrected counts per minute (CCPM) of iDC and day 6 MDC from transwell co-cultures 
that were incubated with CD4+CD25- T cells to assess their allostimulatory capacity. Data are from 
2 different MSC donors and the experiment was performed in triplo; significance is relative to iDC 
(*p<0.05, ***p<0.001).
Figure 1. MSC prevent the differentiation of iDC.
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Both IL-6 and IL-10 concentrations are increased in co-cultures of mono-
cytes and MSC
Monocytes were cultured in the presence of IL-4 and GM-CSF and in the presence 
or absence of MSC and cytokine concentrations were measured in cell-free 
culture supernatants of the direct co-cultures. Supernatants from monocytes 
that were cultured in the in the presence of MSC, contained significantly higher 
concentrations of IL-6 and IL-10 than control supernatants, derived from cultures 
without MSC (IL-6: 984.6 ± 122.6 pg/ml versus 333.4 ± 15.1 pg/ml, n = 3, p<0.0001; 
IL-10: 221.6 ± 30.0 pg/ml versus 11.9 ± 4.4 pg/ml, n = 3, p<0.05; Figure 2A-B). 
Cytokine protein levels in the supernatant of monocyte cultures at day 6 for IL-10 (A) and IL-6 (B) in 
the presence or absence of MSC (IL-10: mean ± SEM of 3 independent experiments with 3 different 
monocyte donors and 6 different MSC donors; IL-6: mean of 6 independent experiments with 6 different 
monocyte donors and 7 different MSC donors ; *p<0.05, **p<0.01, ***p<0.001). (C) IL-6 and IL-10 
mRNA expression in MSC after 6 days of culture with and without monocytes and growth factors in a 
transwell co-culture system. Fold change is relative to MSC alone. (D) IL-6 and IL-10 mRNA expression 
in the monocyte-derived cell population from the transwell co-culture at day 6 of differentiation in the 
absence or presence of MSC. Fold change is relative to MDC differentiated in the absence of MSC. (E) 
IL-6 secretion of MSC after 2 days of culture in fresh medium following 6 days culture with or without 
growth factors and monocytes. (F) IL-6 secretion of monocyte-derived-cells (MDC) after 2 days of 
culture in fresh medium following differentiation in the absence or presence of MSC. (C-F: data are 
mean ± SEM of 3 different MSC donors, *p<0.05, **p<0.01, ***p<0.001).
Figure 2. Cytokine expression in MSC and monocytes in the co-cultures.
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Cytokine expression by MSC and monocytes
The MSC-induced changes in surface marker phenotype and cytokine 
concentrations in the monocyte cultures were also observed when the experiments 
were performed in a transwell system (data not shown). To assess which 
population was responsible for the observed increase in cytokine concentrations, 
the MSC and the monocyte-derived cell populations from such transwell 
cultures were assessed at day 6 for expression of IL-6 and IL-10 mRNA. Neither 
unstimulated MSC, nor MSC cultured in the presence of IL-4 and GM-CSF and in 
the presence or absence of monocytes, were found to express IL-10 mRNA (Figure 
2C). In agreement with this observation, IL-10 protein was not detected in culture 
supernatants from unstimulated MSC or from MSC cultured in the presence of 
IL-4 and GM-CSF (data not shown). Monocytes-derived cells, however, expressed 
detectable levels of IL-10 mRNA (fold change of 3.47x10-4 ± 8.5x10-5 relative to 
β-actin) and these expression levels were considerably increased in the presence 
of MSC (p<0.05; Figure 2D). These data indicate that the IL-10 protein detected in 
the supernatants of monocyte-MSC co-cultures was produced by the monocyte-
derived cell population. 
Next, we analyzed expression levels of IL-6. Figure 2C shows that unstimulated 
MSC express IL-6 mRNA. A 5-fold increase in the average level of IL-6 mRNA 
expression was observed in MSC from cultures containing IL-4 and GM-CSF, but 
this increase did not reach statistical significance (p = 0.06), which was probably 
due to the high variation that was observed between the different MSC samples. 
No further increase in IL-6 mRNA expression was observed in MSC that were co-
cultured with monocytes. After the 6 days co-culture, MSC and monocytes were 
separated and cultured for another 2 days to measure the cytokine concentrations 
secreted by both populations after co-culture. Similar to the IL-6 mRNA expression 
in MSC, the concentrations of IL-6 protein in culture supernatants of MSC cultured 
in the presence of IL-4 and GM-CSF and in the presence or absence of monocytes 
were not significantly increased compared to unstimulated MSC (Figure 2E).
IL-6 mRNA was also expressed in the monocyte-derived iDC. Significantly increased 
expression levels (p<0.001) were found in monocyte-derived populations that were 
generated in the presence of MSC (Figure 2D). In agreement, the concentrations of 
IL-6 in supernatant of monocytes cultured for an additional 2 days after the 6 day 
MSC-monocyte co-culture were significantly increased compared to the control 
culture of monocytes with IL-4 and GM-CSF (p<0.05; Figure 2F).
Secreted factors from unstimulated MSC are responsible for the inhibition 
of monocyte differentiation
The observation that MSC also displayed their inhibitory effect on the 
differentiation of monocytes when the co-cultures were performed in a transwell 
system, showed that cell-cell contact between monocytes and MSC was not 
required and that soluble factors were responsible for this effect. We investigated 
whether these soluble factors were secreted by culture-expanded MSC or only by 
MSC stimulated in the co-cultures. Therefore, three types of conditioned medium 
were collected and tested for their ability to inhibit monocyte differentiation: 1) 
conditioned medium from unstimulated MSC (MSC-CM), 2) conditioned medium 
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from MSC cultured with the growth factors IL-4 and GM-CSF (MSC+GF CM) and 3) 
conditioned medium from the monocyte-MSC direct co-cultures (MSC+mono CM). 
Figure 3 shows that the differentiation of CD1a-CD14+ monocytes into CD1a+CD14- 
iDC was completely inhibited in the presence of CM derived from stimulated, but 
also from unstimulated MSC. This shows that the MSC constitutively produce 
and secrete the essential factor(s) that cause their inhibitory effect on monocyte 
differentiation to iDC.  
Monocytes were differentiated in the presence of different conditioned media. (A) Representative 
dotplots of monocytes differentiated for 6 days in the presence of various conditioned media. (B) 
Cumulative data of CD1a and CD14 expression on day 6 monocytes differentiated in the presence of 
various conditioned media (data are collected from two different MSC donors and 1 monocyte donor). 
MSC-CM, MSC conditioned medium; MSC+GF CM, conditioned medium from MSC cultures containing 
the growth factors IL-4 and GM-CSF;  MSC+mono CM, conditioned medium from the monocytes 
differentiated with growth factors in the presence of MSC in a direct co-culture. Statistical significance 
is compared to control (*p<0.05,**p<0.01).
Figure 3. Secreted factors from unstimulated MSC are responsible for the inhibition of monocyte 
differentiation.
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The role of IL-10 and IL-6 in the MSC-mediated inhibition of monocyte differentiation was 
investigated. (A) Adding a neutralizing antibody against IL-10 did not restore the iDC formation 
(data are representative dotplots from 2 independent experiments with 2 different MSC donors and 2 
different monocyte donors). (B, C) The addition of a neutralizing antibody against IL-6 (2.5 µg/ml) to 
the transwell co-culture significantly reduces the inhibitory effect of MSC (data are of 3 independent 
experiments with 4 different MSC donors and 4 different monocyte donors; means ± SEM of; Statistical 
analysis was performed using the Wilcoxon signed rank test *p<0.05). (D, E) The increase of IL-6 and 
IL-10 mRNA expression on day 6 monocytes (fold change is relative to iDC)(D) and protein secretion in 
the co-culture at day 6 (E) is reversed when an IL-6 neutralizing antibody is added to the culture (data 
are means ± SD of two different MSC donors and 1 monocyte donor; *p<0.05).
Figure 4. IL-6, but not IL-10, is directly involved in the inhibitory effect of MSC on monocyte 
differentiation.
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Role of IL-6 and IL-10 in the MSC-induced inhibition of monocyte differen-
tiation
To study the exact role of IL-6 and IL-10 in the inhibition of monocyte differentiation 
by MSC, neutralizing antibodies against IL-6 and IL-10 were added to the transwell 
co-cultures. Addition of neutralizing antibodies against IL-10 did not result in a 
restored iDC formation (Figure 4A). Addition of neutralizing antibodies against IL-
6, however, caused a partly, but significant reduction of the inhibitory effect of MSC 
and resulted in an increased CD1a expression and a decrease in the expression of 
CD14 on monocytes (Figure 4B-C). This neutralization of IL-6 substantially reduced 
the upregulation of IL-6 mRNA and IL-10 mRNA expression in the monocyte-
derived population (Figure 4D) and reduced IL-10 protein concentrations (Figure 
4E) in the monocytes cultures with MSC or MSC-CM. 
We confirmed the observation that addition of either IL-6 or IL-10 resulted in 
inhibition of the monocyte differentiation (Figure 5A-B). However, since MSC 
do not produce IL-10 (Figure 2), only IL-6 can be an MSC-derived factor that is 
relevant for the inhibitory effect of MSC. Indeed, we showed that addition of only 
IL-6 to the monocyte cultures induces IL-10 expression in monocytes, similar to 
the effect of MSC or MSC-CM (Figure 5A). To confirm that IL-6 is indeed the key 
factor produced by MSC, we depleted IL-6 from MSC-CM and studied the effect of 
this IL-6 depletion on monocyte differentiation. After depletion of IL-6, 84-96% of 
the IL-6 was depleted from the MSC-CM. In Figure 5C is shown that the inhibition 
of monocyte differentiation by MSC-CM was reversed by depletion of IL-6 from 
the CM. IL-6 depletion completely reversed the formation of a CD14+ monocyte-
derived population, but did not reverse the MSC-CM-mediated inhibition of 
CD1a upregulation. Functional testing revealed that the MSC-CM-induced IL-
10 secretion in the monocyte cultures was completely abolished following IL-6 
depletion (Figure 5D). The allostimulatory capacity, however, was not restored by 
depleting IL-6 from the MSC-CM (figure 5E). Overall, our results show that MSC-
derived IL-6 is an essential factor for the inhibition of monocyte differentiation 
by MSC and for inducing an IL-10 producing, monocyte-derived CD14+CD1a- cell 
population. The neutralizing and depletion experiments show that IL-6 is an 
important, but not the only factor, that is produced by MSC to exert the inhibitory 
effect on monocyte differentiation. 
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IL-6 (A) and IL-10 (B) were added to the monocyte differentiation cultures. Both IL-6 and IL-10 inhibit the 
differentiation to iDC similar to the effect of co-culture with MSC/MSC-CM and addition of IL-6 directly 
increases the IL-10 secretion by monocyte-derived cells (A) (data are means ± SD from two different 
MSC; *p<0.05). (C) Depletion of IL-6 from the MSC conditioned medium partly reverses the inhibiting 
effect of MSC on the monocyte-derived iDC differentiation (representative dotplot of 3 different MSC 
donors and 2 different monocyte donors. (D) MSC-derived IL-6 drives the IL-10 upregulation in the 
monocyte-derived cell population (C,D: data are means ± SD from two different MSC ; ***p<0.001). (E) 
Corrected counts per minute (CCPM) of iDC and day 6 MDC from cultures in MSC-CM and IL-6 depleted 
MSC-CM that were incubated with CD4+CD25- T cells to assess their allostimulatory capacity. Data are 
from 2 different MSC donors and the experiment was performed in triplo; significance is relative to iDC 
(*p<0.05, **p<0.01, ***p<0.001).
Figure 5. IL-6 is the key factor in the MSC-induced inhibition of monocyte differentiation.
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Discussion
It has been acknowledged that MSC inhibit the differentiation of monocytes 
towards iDC. The cytokines IL-6 and IL-10 have been described to play a role 
in the differentiation of monocytes towards immature dendritic cells (iDC) 21,22. 
However, the role of these cytokines in the MSC-induced inhibition of this process 
is still unclear. In this study, we have used an MSC-monocyte co-culture system 
to identify the cytokines that are crucial in this process and reveal their exact 
cellular source of production. The addition of MSC to the monocyte cultures 
containing IL-4 and GM-CSF inhibited the monocyte-derived iDC differentiation 
and significantly increased the concentrations of the cytokines IL-6 and IL-10. 
Transwell experiments showed that cell-cell contact was not required for the 
inhibiting effect of MSC on monocyte differentiation, indicating that soluble 
factors were responsible for this effect. Subsequent experiments with MSC-CM 
showed that unstimulated MSC produced the soluble factors responsible for 
inhibition of monocyte differentiation. Previous studies suggested IL-6 to play a 
role in the inhibitory effect of MSC on the differentiation of monocytes to dendritic 
cells 19,20. Whether this would be a direct or indirect effect remained unclear since 
both monocytes and MSC are capable of IL-6 production and secretion. We show 
that IL-6 production by MSC is constitutive and not significantly enhanced upon 
contact with monocytes. Since the effect of MSC could be replaced by MSC-CM, 
we considered MSC-derived IL-6 to be responsible for the MSC-induced inhibition 
of monocytes differentiation. Indeed, addition of neutralizing antibodies to IL-6 
significantly reversed the inhibitory effect of MSC and depletion of IL-6 reversed 
the inhibitory effect of MSC-CM. These data clearly indicate that MSC-derived IL-6 
regulates in vitro monocyte differentiation, thereby skewing monocytes towards an 
IL-10 producing cell type with a reduced allostimulatory capacity. Additional factors 
might however play a role in the complete inhibition of monocyte differentiation 
towards iDC by MSC, since the allostimulatory capacity of the monocyte-derived 
cells was not restored by depleting IL-6 from the MSC-CM. 
We found that, in spite of a number of reports making this claim 10,25-32, MSC do 
not produce IL-10, but that IL-10 is exclusively produced by monocytes in this 
system. Several reports claiming that the immunomodulatory properties of MSC 
are mediated by IL-10 have used antibodies to neutralize IL-10 in co-cultures 
of MSC and other cell types, including monocytes. These studies were therefore 
not designed to identify the cells that produce IL-10. Many reports indicate that 
MSC need to be activated in order to exert their immunomodulatory activities or to 
produce IL-10 26,33,34. Our data clearly show that activation of MSC is not required 
for the IL-10 induction in monocytes.
Activated monocytes have been shown to increase their IL-10 expression upon 
IL-10 exposure 35. Such increased IL-10 production could further enhance the 
immunomodulatory effect of MSC. Increased IL-10 secretion is a characteristic 
of type II activated macrophages, which have an immunomodulatory, anti-
inflammatory function 36,37. Type-II-activated macrophages have also been shown 
to be able to induce regulatory T cells 38, another potential additional indirect 
immunomodulatory effect of MSC. 
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Taken together, we propose the hypothesis that MSC, by inducing IL-10 production 
in monocyte-derived cells, play a powerful regulatory role in multiple anti-
inflammatory mechanisms (Figure 6), which could explain their clinical benefits 
in immunotherapy e.g. the treatment of GvHD. Thereby MSC may act as potent 
modulators of the (innate) immune response inducing an anti-inflammatory 
environment.
By secreting IL-6, MSC skew monocytes from differentiation towards an antigen-presenting DC 
towards an anti-inflammatory cell that produces IL-10.  
Figure 6. Hypothetical model of immunomodulating mechanisms exerted by MSC through production 
of IL-6.
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Abstract
Multipotent stromal cells (MSC) have been shown to possess immunomodulatory 
capacities and are therefore explored as a novel cellular therapy. One of the 
mechanisms through which MSC modulate immune responses is by the promotion 
of regulatory T cell (Treg) formation. In this study we focused on the cellular 
interactions and secreted factors that are essential in this process.
Using an in vitro culture system, we showed that culture-expanded bone marrow 
derived MSC promote the generation of CD4+CD25hiFoxP3+ T cells in human PBMC 
populations and that these populations are functionally suppressive. Similar 
results were obtained with MSC-conditioned medium, indicating that this process 
is dependent on soluble factors secreted by the MSC. Antibody neutralization 
studies showed that TGF-β1 mediates induction of Tregs. TGF-β1 is constitutively 
secreted by MSC, suggesting that the MSC-induced generation of Tregs by TGF-β1 
was independent of the interaction between MSC and PBMC.
Monocyte-depletion studies showed that monocytes are indispensable for 
MSC-induced Treg formation. MSC promote the survival of monocytes and 
induce differentiation towards macrophage type 2 cells that express CD206 and 
CD163 and secrete high levels of IL-10 and CCL-18, which is mediated by as yet 
unidentified MSC-derived soluble factors. CCL18 proved to be responsible for the 
observed Treg induction. 
These data indicate that MSC promote the generation of Tregs. Both the direct 
pathway through the constitutive production of TGF-β1 and the indirect novel 
pathway involving the differentiation of monocytes towards CCL18 producing, 
type 2 macrophages are essential for the generation of Tregs induced by MSC. 
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Introduction 
Regulatory T cells (Tregs) are the primary mediators of peripheral tolerance, which 
maintain immune homeostasis and are moderators of inflammation. Several 
types of Tregs have been described, including naturally occurring Tregs (nTregs), 
that develop in the thymus, and induced Tregs (iTregs), that are generated in the 
periphery and arise from conventional T cells 1;2. The mechanisms by which iTregs 
are induced have not been fully elucidated. The transcription factor forkhead 
box P3 (FoxP3), which is a key regulatory gene for the development of Tregs 3, is 
expressed in both nTregs and iTregs.
Multipotent stromal cells (MSC) display immunomodulatory capacities, including 
the capacity to suppress the proliferation of T cells, B cells and IL-2 stimulated NK 
cells 4-6 and to inhibit the differentiation and maturation of dendritic cells 7. Another 
important mechanism by which MSC exert their immunomodulatory functions is 
the induction of Tregs. In in vivo studies regarding allergic airway inflammation 
and heart transplantation, MSC were shown to induce the generation of Tregs 8;9. 
Understanding the mechanisms behind the MSC induced formation of Tregs is 
important for the application of MSC as a therapeutic agent. 
The mechanisms by which MSC induce the generation of Tregs have been studied 
in vitro. These studies involved co-cultures of MSC and PBMC and showed the 
generation of functionally suppressive CD4+CD25hiFoxP3+ Tregs 10-14. According 
to some studies soluble factors are involved, while other studies indicate the 
requirement of cell-cell contact. The molecular pathways that are involved in 
the MSC-induced Treg formation have not yet been fully identified. English and 
colleagues claimed the involvement of TGF-β1 and PGE2 12, while others found 
that MSC-induced Treg formation was not reduced by neutralizing antibodies 
against these factors 13. 
In this study, we explored the cellular and molecular pathways underlying the Treg 
promoting effect of MSC. We found that the MSC-induced formation of Tregs is 
driven by TGF-β1, which is produced by MSC, and by CCL18, which is produced by 
monocytes upon interaction with MSC. 
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Materials and methods
Generation of human MSC and PBMC
After obtaining informed consent, adult bone marrow was harvested from 
healthy donors or orthopedic patients. Mononuclear cells were isolated using 
a Ficoll-Paque density gradient (1.077 g/cm3) and were plated at 1.3 x 105/cm2 
in DMEM-low glucose (Invitrogen Corp., Paisley, UK) supplemented with 10% 
fetal calf serum (FCS; Greiner Bio-one, Alphen a/d Rijn, The Netherlands) and 
Penicillin/Streptomycin (P/S; Invitrogen Corp., Paisley, UK). After 3-4 days, non-
adherent cells were removed and medium was refreshed every 3-4 days until cells 
reached approximately 90% confluency. The MSC monolayer was detached using 
trypsin/EDTA (Invitrogen Corp., Paisley, UK) and reseeded at 4,000/cm2 for further 
expansion. The MSC were characterized by flowcytometric analysis and used in 
the experiments at passage 2-5. 
Human PBMC were isolated from buffy coats from healthy donors obtained from 
Sanquin Blood Supply (Leiden, The Netherlands) using a Ficoll-Paque density 
gradient. CD4+ T cells were isolated from PBMC by MACS using a cocktail of biotin-
labeled antibodies against CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCRγ/δ 
and CD235a and anti-biotin microbeads followed by separation on a MACS LS 
column according to the manufacturer’s recommendations (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). Monocytes were isolated or depleted from 
PBMC populations by several rounds of plastic adherence or by MACS using CD14 
microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), followed by 
MACS LS column separation according to the manufacturer’s recommendations.
PBMC-MSC co-cultures
To assess the capacity of MSC to induce the generation of Tregs, transwell co-
cultures were performed as described earlier 14. In short, PBMC were co-cultured 
with allogeneic MSC for one week followed by one week of culture in the absence 
of MSC. As a control experiment, a co-culture of PBMC with autologous MSC was 
performed. At day 0, 100,000 MSC were plated in 12-wells plates in RPMI medium 
(Invitrogen Corp., Paisley, UK) containing P/S, L-glutamin (Invitrogen Corp., Paisley, 
UK) and 10% FCS and in a transwell insert (pore size 0.4 μM, Corning, Inc, Lowell, 
MA, USA) 500,000 PBMC were added. At day 7, PBMC were harvested from the 
inserts and washed (day 7-PBMC). Cells were counted and resuspended in fresh 
medium and cultured for 7 days in the absence of MSC. At day 14, PBMC were 
harvested (day 14-PBMC), counted and analyzed by flowcytometry.
In addition to the transwell co-cultures, MSC-conditioned medium (CM) was tested 
for its ability to promote generation of CD4+CD25hiFoxP3+ T cells. Near-confluent 
cultures of MSC were cultured with RPMI supplemented with P/S, L-glutamin and 
10% FCS for 5-7 days. The cells were harvested and counted and the cell-free 
culture supernatant was concentrated using 10K Centriprep Centrifugal filters 
(Millipore Corp, Billerica, MA, USA). PBMC were cultured for 7 days in a 12-wells 
plate with a CM equivalent of 100,000 MSC supplemented with until 1 ml with 
fresh RPMI containing P/S and L-glutamin. At day 7, the PBMC were harvested and 
resuspended in fresh medium and cultured for another 7 days. At day 14, PBMC 
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were harvested, counted and analyzed by using flow cytometry. 
The role of molecular factors in the induction of Treg formation by MSC was 
assessed by blocking experiments. In the first week of co-culture, antibodies 
against IL-6 (0.2-1.0 μg/ml), IFN-γ (1.0 μg/ml) and CCL18 (0.5 – 2.0 μg/ml; all from 
R&D systems Europe Ltd., Abingdon, UK) and an inhibitor of the TFG-β1-receptor 
(TFG-β1-R) (10 μM, Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) were 
added to the medium. Control experiments were performed by addition of equal 
concentrations of a non-specific antibody of the same isotype to the co-cultures. 
The role of HO-1 was determined by adding the inhibiting agent tin protoporphyrin 
IX dichloride (SnPP, 10 μM, Tocris Bioscience, Bristol, UK). 
Monocyte-MSC co-cultures
To directly investigate the effect of MSC on monocytes, 3 day cultures were 
performed of freshly isolated monocytes in unconcentrated CM diluted with 
RPMI medium in a ratio 2:1. To reveal an effect of MSC on monocytes, apart from 
their monocyte survival-enhancing effect, we compared monocytes that were 
stimulated with CM versus RPMI medium with and without the addition of 5 ng/ml 
M-CSF (Peprotech EC Ltd. London, UK), neutralizing antibodies against the M-CSF-
receptor (concentration [1:100] –[1:500]), the inhibitor of the TFG-β1-receptor 
(10 uM) or recombinant TFG-β1 (10 ng/ml; BD Biosciences, San Diego, CA, USA). 
At day 3 of the culture the monocytes were harvested and analyzed for surface 
marker expression using flow cytometry, counted and assessed for viability using 
eosine staining. RNA was extracted for gene expression analysis using RNease 
columns (Qiagen GmbH, Hilden, Germany). Cell-free supernatants were collected 
and stored at -20°C for analysis of cytokine concentrations. 
Functionality assay
For some experiments, PBMC at day 14 of the PBMC-MSC co-culture were 
separated by FACS (FACSAria III cell sorter; BD Biosciences, San Diego, CA, USA) 
in a CD25- fraction and a CD25hi fraction. The complete population of PBMC that 
were cultured in the presence and absence of MSC and the sorted CD25- fraction 
and a CD25hi fraction PBMC cultured in the presence of MSC were tested for their 
immunosuppressive capacity in an autologous suppression assay. To this end, 
autologous CD4+CD25- cells were isolated from PBMC (using the CD4+CD25+ 
regulatory T cell isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany)). CD4 T cells were isolated from PBMC as described above, followed by 
separation of CD4+CD25+ and CD4+CD25- T cells by CD25 microbeads according 
to manufacturer’s recommendations (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). CD4+CD25- T cells (100,000/well) were stimulated with human 
T-activator CD3/CD28 dynabeads (Invitrogen Corp., Paisley, UK) in a bead:cell 
ratio 1:5. To this culture, day 14-PBMC, day 14-CD25- or day 14-CD25hi cells were 
added in a 1:1 ratio with CD4+CD25- T cells. After 5 days, the cells were pulsed with 
[3H]-thymidine (0.5 μCi/well) and incubated for 16 h at 37°C. The cultures were 
harvested on a glass fiber filter and thymidine incorporation was measured with a 
liquid scintillation counter (Wallac, Turku, Finland).
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Analysis of cytokine production
Cytokine concentrations were measured in the cell-free supernatant of day 14 
from the PBMC culture in the presence and absence of CM (IL-10) and in the 
supernatant from the 3-day monocyte cultures with and without M-CSF and/or CM 
(IL-10, IL-12, and CCL18). Constitutive production by MSC of the cytokines M-CSF 
and TGF-β1 were measured in cell-free culture supernatant of unstimulated of 
MSC. Cytokine concentrations were measured using sandwich ELISA (IL-10, IL-12 
and TGF-β1 and : BD Biosciences, San Diego, CA, USA; M-CSF and CCL18:  R&D 
systems Europe Ltd., Abingdon, UK) or a Bio-Plex Pro Human Cytokine 27-plex 
panel (Bio-Rad laboratories, Inc, Hercules, CA, USA). Cytokine concentrations 
were determined using a standard curve. Statistical analysis was performed using 
a One-way-ANOVA and the differences between groups were analyzed using a 
paired T-test. A P < .05 was considered statistically significant.
Flow cytometry
Antibodies used for flowcytometric analysis of PBMC and monocytes were 
anti-CD4 PerCP-Cy5.5, anti-CD69 FITC, anti-CD25 PE-Cy7, anti-CD14 PE, anti-
CD127 biotin, anti-CD206 APC (BD Biosciences, San Diego, CA, USA), anti-
CD25 PE (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), anti-FoxP3 APC 
(eBioscience, Inc., San Diego, CA, USA), anti-CD163 PerCP-Cy5.5, anti-CD80 PE-
Cy7 (Biolegend, Inc., San Diego, CA, USA) and streptavidin-Pacific blue (Invitrogen 
Corp., Paisley, UK). MSC were analyzed for expression of surface markers using 
FITC-conjugated and PE-conjugated antibodies against: CD90, CD73, CD45, CD34, 
HLA-DR, HLA-ABC, CD80 (BD Biosciences, San Diego, CA, USA) and CD105 (Ancell 
Corp., Bayport, MN, USA). For surface staining, primary antibodies were added and 
the cells were incubated for 30 minutes at 4°C in the dark. Cells were washed 
with PBS/1% albumin, secondary antibodies were added and incubated for 30 
minutes at 4°C in the dark. For intracellular FoxP3 staining, the FoxP3 staining 
buffer kit (eBioscience, Inc., San Diego, CA, USA) was used. All stainings were 
analyzed using a FACSCanto II (BD Biosciences, San Diego, CA, USA). The analysis 
of the acquired data was done with FlowJo software version 7.6.1 (Tree Star, Inc., 
Ashland, OR, USA). Mean fluorescence intensity (MFI) was analysed and statistical 
analysis was performed using a One-way-ANOVA, the differences between groups 
were analyzed using a paired T-test and a P < .05 was considered statistically 
significant.
Gene expression analysis
To study the effect of MSC on monocytes we performed a microarray analysis 
on monocytes cultured for 3 days with CM and/or M-CSF. From these monocyte 
populations, RNA was extracted using the RNeasy micro kit (Qiagen GmbH, Hilden, 
Germany). For microarray analysis, the RNA was amplified and biotinylated using 
the Illumina® Totalprep™ RNA amplification kit (Life Technologies Europe BV, 
Bleiswijk, The Netherlands). The samples were hybridized on a HumanHT-12 v4 
Expression BeadChip according to the manufacturer’s instructions. Chips were 
scanned on an Illumina BeadArray 500GX reader and analyzed with BeadStudio 
software (all from Illumina Inc, San Diego, CA, USA). Gene expression data were 
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obtained from BeadStudio and processed in R using Bioconductor 15 and the R 
beadarray package 16, using the BASH algorithm for outlier detection. The remaining 
bead information was summarized and normalized using quantile normalization. 
Due to considerable donor variation between the different monocyte sources, 
differentially expressed genes were determined using the RankProd 17 method, 
considering a percentage false positive (PFP) rate of 0.05 significant. Gene set 
enrichment analysis was performed using the Broad Institute GSEA tool18.
For RT-qPCR analysis cDNA was synthesized with Superscript III RT (Invitrogen 
GmbH, Hilden, Germany). RT-qPCR analyses were performed on a StepOnePlus 
real-time PCR system (Applied Biosystems, Fostercity, CA, USA) using SYBR Green 
reagent (Applied Biosystems). The primer sets used for RT-qPCR are listed in table 
1. All RT-qPCR data were normalized to β-actin expression and analyzed using the 
delta-Ct method. 
Table 1. Primers used for RT-qPCR.
Gene Forward Reverse
IL-10 5’-CCGAGATGCCTTCAGCAGAG-3’ 5’-GGTCTTGGTTCTCAGCTTGG-3’
GAS6 5’-GCCTTTCAGGTCTTCGAGGAG-3’ 5’-GTCAGGCAGGTTTTGCACG-3’
CCL18 5’-ACAAAGAGCTCTGCTGCCTC-3’ 5’-CCCACTTCTTATTGGGGTCA-3’
MMP9 5’-TGGCAGAGGAATACCTGTACC-3’ 5’-GAGTAGTTTTGGATCCAATAGG-3’
β-actin 5’-AGGCATCCTCACCCTGAAGTA-3’ 5’- CACACGCAGCTCATTGTAGA-3’
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Results
Soluble factors produced by MSC promote the formation of                 
CD4+CD25hiFoxP3+ T cells
The formation of Treg was studied in co-cultures of PBMC and MSC. At day 7 of 
these co-cultures, PBMC that were cultured in the presence and absence of MSC 
both contained a population of CD4+CD25hiFoxP3+ T cells (Figure 1A). At day 14 
however, PBMC cultured during the first week in the presence of MSC, contained a 
significantly higher percentage of CD4+CD25hiFoxP3+ T cells than PBMC cultured 
in the absence of MSC (Figure 1A-B; 0.36% versus 10.04%, n=8, P < .001). The 
CD4+CD25hiFoxP3+ T cells did not express the T cell activation marker CD69 and 
CD127  (supplemental Figure 1), compliant with the reported Treg phenotype 19. 
The formation of Tregs induced by MSC was observed when PBMC were cultured 
in the presence of both autologous and allogeneic MSC. Similar results were 
obtained with MSC conditioned medium (CM) (Figure 1C), indicating that factors 
secreted by MSC were responsible for this effect. 
Cytokine measurements in culture supernatants of MSC and PBMC co-cultures 
indicated a three-fold increase in IL-10 concentrations in comparison with culture 
supernatants of PBMC that were cultured in the absence of MSC (Figure 1D; 27.74 
pg/ml versus 10.49 pg/ml, n=4, P = .001). These concentrations fell within the 
standard curve. This indicates that CM induced the cells in the PBMC population 
to secrete IL-10. 
CD4+CD25hiFoxP3+ T cells induced by MSC exhibit regulatory function 
To study the function of the MSC-induced CD4+CD25hiFoxP3+ T cells, the PBMC 
populations generated in the absence and presence of MSC were tested for their 
immunoregulatory capacity. The total PBMC populations obtained at day 14 after 
co-culture with MSC, exhibited a significantly enhanced capacity to suppress 
T cell proliferation compared to PBMC populations that were generated in the 
absence of MSC (Figure 1E). To test specifically whether the CD25hi T cells were 
responsible for this enhanced immunosuppression, PBMC from day 14 of culture in 
the presence of CM were separated in a CD4+CD25- and a CD4+CD25hi T cell fraction 
and tested in a separate autologous suppression assay. At day 14, the CD4+CD25hi 
T cells showed a significantly higher suppression of T cell proliferation compared 
to the CD4+CD25- T cells (Figure 1F), indicating that the CD4+CD25hiFoxP3+ T 
cell population that is formed during co-culture with MSC or CM has regulatory 
function. 
Generation of Tregs is mediated by TGF-β1
In order to identify the factors involved in the MSC-induced Treg formation, antibody 
neutralization and inhibitor experiments were performed. Addition of neutralizing 
antibodies to the TGF-β1-receptor to the PBMC-MSC co-cultures resulted in a 
significantly reduced generation of Tregs compared to control cultures without 
antibodies (4.6%, versus 20.2% P = .02, n = 5, Figure 2A). MSC constitutively 
secreted TGF-β1 as was measured with ELISA in cell free culture supernatant of 
unstimulated MSC (supplemental figure 2). Addition of neutralizing antibodies 
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(A) Representative dotplots of expression of CD4, CD25 and FoxP3 on PBMC on day 7 and 14. (B) The 
percentage of CD4+CD25hi T cells at day 14 is significantly higher in the population that was cultured during 
the first week in in co-culture with MSC compared to PBMC that were cultured without MSC (data are 
means ± SEM from 8 different experiments with 9 different MSC and 7 different PBMC. Statistical analysis 
was performed with a paired T-test; *** P < .001). (C) The presence of CM in the PBMC culture obtains 
similar results as the presence of  MSC (data are means ± SEM from 5 different experiments with 5 different 
MSC and 2 different PBMC. Statistical analysis was performed with a paired T-test;  *** P < .001). (D) The 
IL-10 protein concentrations measured at day 14 were significantly higher in the culture supernatants 
of PBMC cultures in the presence of MSC compared to cultures in the absence of MSC (data are means 
± SEM from 2 different experiments with 3 different MSC and 2 different PBMC. Statistical analysis was 
performed using a paired T-test (** P < .01). (E,F) Autologous CD25- T cells were stimulated with anti-CD3/
CD28 beads (Control) with or without PBMC from the co-culture experiment at day 14 (E) or with sorted 
CD4+CD25- and CD4+CD25+ T cells from the day 14-PBMC cultured with MSC (F). Day 14-PBMC were 
also tested separately for their proliferation upon CD3/CD28 stimulation (negative control). Proliferation 
was measured using 3H-thymidine incorporation after 5 days (data are mean from triplicates ± SEM). 
Statistical analysis was performed with a student’s T-test (** P < .01; *** P < .001).
Figure 1. Coculture of MSC with PBMC results in the induction of functional CD4+CD25hiFoxP3+ T cells. 
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against IL-6 did not result in a significant reduction (P = .38) of the MSC-induced 
generation of Tregs (Figure 2B). As expected, neutralizing antibodies against 
IFN-γ, which is not constitutively expressed by MSC, did not influence the effect of 
MSC on the generation of Tregs (Figure 2C). Finally, addition of the HO-1 inhibitor 
SnPP significantly reduced the population of Tregs at day 14 (13.6%, versus 41.5% 
P = .04, n = 3) (Figure 2D).
(A) Addition of blocking antibodies 
against the TGF-β1-receptor to the 
co-culture during the first week 
significantly reduced the formation 
of Tregs. (B) Addition of neutralizing 
antibodies against IL-6 slightly 
diminished the MSC-induced formation 
of Tregs, but not significant (P = .38). 
(C) Addition of neutralizing antibodies 
against IFN-γ did not affect the MSC 
mediated induction of Tregs. (D) 
Inhibition of HO-1 by SnPP resulted in 
a significant lower percentage of Tregs. 
Means ± SEM are shown of 3-5 different 
experiments with different MSC ad 
PBMC donors in each experiment, 
statistical analysis was performed 
using a students T-test (* P < .05).
Monocytes are required for induction of CD4+CD25hiFoxP3+ T cells
Since CD4+CD25hiFoxP3+ Tregs are derived from the CD4+ T cell population 3, 
we investigated whether a Treg population could be generated by co-culture 
of purified CD4+ T cells with MSC (Figure 3). MSC-induced Tregs could not be 
generated from the purified CD4+ population, as opposed to PBMC, indicating 
that the PBMC population contains accessory cells mediating the formation of 
Tregs (Figure 3A). Following depletion of monocytes from the PBMC population, no 
Treg population could be formed (Figure 3A-B). To exclude the possibility that the 
depletion procedure interfered with the formation of Tregs, we added monocytes 
back to the monocyte-depleted PBMC populations. This restored the formation of 
the Treg population (Figure 3A-B). These data show that monocytes are essential 
in mediating MSC-induced formation of Tregs. 
MSC promote the survival of monocytes 
Since monocytes were essential for the MSC-induced Treg formation, we focused 
on the effect of MSC and CM on monocytes in PBMC-MSC co-cultures and by 
performing cultures of freshly isolated monocytes stimulated with CM. In the 
presence of MSC, the PBMC cultures contained a higher percentage of CD14+CD16+ 
cells after 4 and 7 days compared to cultures in the absence of MSC (Figure 4A). 
Figure 2. The induction of Treg formation by MSC is mediated by several factors. 
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Staining with Annexin V and CD1a showed that the monocytes that lose CD14 
undergo apoptosis and do not differentiate towards dendritic cells (data not 
shown), indicating that MSC promote survival of monocytes in the culture. This 
survival-promoting effect was confirmed in 3-day cultures of freshly isolated 
monocytes in the presence of CM. Similar results were observed in cultures of 
freshly isolated monocytes stimulated with M-CSF. M-CSF, a factor that is produced 
by MSC (supplemental figure 2) and is known to promote monocyte survival, did 
not further enhance the effect of CM on monocyte survival (Figure 4B). 
To explore the transcriptional changes in monocytes in response to MSC exposure, 
we performed a genome wide gene expression profiling of monocytes from 3 
different donors. Comparison of the two datasets (‘CM stimulated monocytes 
versus unstimulated monocytes’ and ‘CM + M-CSF stimulated monocytes versus 
M-CSF stimulated monocytes’), resulted in 43 overlapping unique genes, that were 
differentially expressed after stimulation with CM (Figure 4C). Gene set enrichment 
analysis showed downregulation of apoptosis-related genes 20 in monocytes in 
response to CM, in line with the survival promoting effect of MSC on monocytes 
(supplemental Figure 3).
(A) total PBMC (Ai), purified CD4+ Tcells (Aii) and 
monocyte-depleted (Aiii) and repleted PBMC 
(Aiv) were co-cultured with MSC and tested 
for their ability to generate CD4+CD25hiFoxP3+ 
T cells (n=5). Results are shown as 
representative dotplots. (B) Cumulative data 
of 5 experiments. The population CD4+CD25hi T 
cells is significantly lower when either MSC or 
monocytes are depleted from the culture (data 
are means ± SEM of 5 different experiments, 
statistical analysis was performed using a 
students T-test (* P < .05)).
Figure 3. Monocytes are indispensable for the induction of CD4+CD25hiFoxP3+ T cells.
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(A) In the presence of MSC, a higher percentage of CD14+CD16+ monocytes is present in the PBMC 
population after 7 days of culture than in PBMC cultured without MSC. (B) Stimulation with either M-CSF 
or CM increases survival of monocytes in a 3 day culture compared to control cultures (data are means 
± SEM from 3 different MSC; *** P = .001). (C) Heatmap representing upregulated genes in monocytes 
cultured in the presence of CM compared to control cultures of monocytes cultured in the absence CM. 
The Venn-diagram represents the overlapping differentially regulated genes between the comparison of 
CM versus control cultures and the CM+M-CSF versus M-CSF cultures.
Figure 4. MSC promote survival of monocytes. 
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(A) The mean fluorescence intensities (MFI) of CD206, CD163 and CD80 within the CD14+ 
population are shown (data are means ± SEM from 2 experiments with 3 different MSC donors; 
** P < .01). Expression of surface markers on monocytes (B) and IL-10 concentrations in culture 
supernatant (C) after a 3 days stimulation with M-CSF and/or CM (data are means ± SEM from 5 
different monocyte donors and CM from 2 different MSC; * = compared to control, ** P < .01, *** 
P < .001; # = compared to M-CSF, # P < .05, ## P < .01, ### P < .001). (D) IL-10 gene expression 
is increased in monocytes that were cultured with CM compared to M-CSF and control cultures 
(data are means ± SD from 3 different monocyte donors and 2 different MSC donors; * P < .05; 
** P < .01). (E) CCL18, GAS6 and MMP9 gene expression in monocytes that were cultured for 3 
days in CM and/or M-CSF (data are means ± SD from 3 different monocyte donors and 2 MSC 
donors; * P < .05; ** P < .01; # P < .05, ## P < .01, ### P < .001). 
Figure 5. MSC-CM induces skewing of monocytes towards differentiation into a type-II macrophage. 
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MSC skew monocytes towards an anti-inflammatory profile
Phenotype analysis
To further study the effect of MSC on monocytes, phenotypic changes of 
monocytes during co-cultures with MSC were studied. At day 7 of the co-cultures, 
the expression of the macrophage type 2 markers CD206 and CD163 and of CD80 
was increased on monocytes compared to the cultures without MSC (Figure 5A). 
Further investigation of the effect of MSC on freshly isolated monocytes showed 
that M-CSF as well as CM increased the expression of the surface markers CD163, 
CD206 and CD80 on monocytes, indicating a skewing of monocytes towards a 
macrophage type 2 phenotype (Figure 5B). The expression of CD163 was further 
increased in the presence of both M-CSF and CM, which shows an additive 
effect of CM. Expression of CD86 was not changed by M-CSF alone, but was 
significantly decreased after culture with CM. To investigate the involvement of 
M-CSF in the effect of CM we added neutralizing antibodies against the M-CSF-
receptor (M-CSF-R) to monocytes cultured in the presence of CM. We found that 
the increased expression of the surface markers CD80, CD163 and CD206 on 
monocytes cultured in the presence of CM (figure 6A) as well as the increase in 
survival (figure 6B) was reversed in the presence of neutralizing antibodies against 
M-CSF-R, showing that M-CSF is responsible for these effects.
Altogether, these surface marker expression data indicate that some of the effects 
of CM can be explained by M-CSF, but that additional soluble factors, present in 
the CM, are involved in skewing of monocytes towards type 2 macrophages.  
Cytokine secretion
Monocytes were also functionally tested for cytokine secretion after stimulation 
with CM and/or M-CSF. Stimulation of monocytes with CM or M-CSF resulted in 
significantly (P < .001) increased concentrations of IL-10 in the culture supernatant 
at day 3. IL-10 concentrations were further increased following stimulation of 
monocytes with both CM and M-CSF (Figure 5C). Expression levels of IL-10 mRNA 
were similar in unstimulated monocytes and monocytes that were stimulated with 
M-CSF (Figure 5D), suggesting that the observed increase in IL-10 concentrations 
in the culture supernatant was a result of increased monocyte survival. Stimulation 
of monocytes with CM, however, significantly increased the expression of IL-10 
mRNA by monocytes compared to the cultures of monocytes in the absence of CM. 
The combination of CM and M-CSF did not further increase the mRNA expression 
of IL-10 in monocytes compared to CM alone, suggesting that the increased IL-10 
secretion that was observed after monocyte stimulation with the combination of 
CM and M-CSF was regulated at a post-transcriptional level.  Moreover, the CM-
induced increase in IL-10 secretion was not significantly reversed by addition of 
neutralizing antibodies against M-CSF-R (figure 6C), indicating that the M-CSF is 
not responsible for the observed IL-10 secretion by monocytes. Taken together, 
these data indicate that CM induced IL-10 production in monocytes and that 
CM is superior to M-CSF alone in this effect. IL-12 protein was not detectable 
in supernatant of monocyte cultures stimulated with CM. Further analysis of 
cytokine concentrations in the culture supernatant of monocytes showed reduced 
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(A) The mean fluorescence intensities 
(MFI) of CD206, CD163 and CD80 within 
the CD14+ population are shown (data 
are means ± SEM from 2 different 
MSC donors and 2 different monocyte 
donors; ** P < .01). (B) Addition of an 
antibody against the M-CSF-R reversed 
the CM-induced increased survival of 
monocytes in a 3 day culture. (C) IL-10 
concentrations in culture supernatant 
after a 3 days of culture of monocytes 
in the presence of CM and CM + anti-
M-CSF-R antibodies (data are means ± 
SEM from 2 different MSC donors and 
2 different monocyte donors; * P < .05). 
Figure 6. M-CSF is partly responsible for the MSC-induced skewing of monocytes towards type-II 
macrophages.
(A) CCL18 protein concentrations measured with ELISA at day 3 of the monocyte culture are increased 
when monocytes were stimulated with CM. Addition of an inhibitor of the TGF-β1-receptor did not 
reverse the effect of CM and recombinant TGF-β1 did not induce CCL18 secretion by monocytes. 
(Data are means of 5 monocyte donors and 2 MSC donors; * = compared to control, * P < .05, ** P < 
.01; # = compared to M-CSF, ## P < .01).  (B) Representative dotplots of expression of CD4 and CD25 
on day 14-PBMC from control cultures and from PBMC-CM co-cultures in the presence of neutralizing 
antibodies against CCL18. (C) The percentage of CD4+CD25hi T cells at day 14 is significantly lower 
in the population that was cultured during the first week in the presence of aCCL18 compared to 
PBMC that were cultured in control PBMC-CM cultures (data are means ± SEM from 2 different PBMC. 
Statistical analysis was performed with a student’s T-test; ** P < .01. (D) Hypothetical model of Treg 
formation induced by MSC, both the direct pathway via MSC-derived TGF-β1 and the indirect pathway 
via the modulation of monocytes are crucially involved in the MSC-induced Treg formation. 
Figure 7. MSC-induced and monocyte-dependent Treg formation is mediated by CCL18.
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concentrations of the pro-inflammatory cytokines IL-1b, MIP-1a, MIP-1b and 
RANTES in the culture supernatant of monocytes that were cultured in the presence 
of CM compared to M-CSF (supplemental Figure 4).  
Transcriptional profiling of monocytes
Gene expression profiling of monocytes showed that by CM stimulation of 
monocytes resulted in upregulation of several genes, including CD163, GAS6, 
CCL18, PLTP, that are associated with the type 2 macrophage phenotype (Figure 
4C). Additionally, gene set enrichment analysis showed that the STAT3 pathway 
was activated in monocytes that were cultured in the presence of CM 21, which is 
another characteristic of type 2 macrophages (supplemental Figure 3). Microarray 
results were confirmed and validated by RT-qPCR in samples from other monocyte 
donors and stimulated with CM from another MSC donor than those used for 
the microarray analysis. The expression of genes encoding CCL18 and GAS6 
was indeed upregulated in monocytes that were stimulated with CM, but not in 
monocytes that were stimulated with M-CSF (Figure 5E). As expected, MMP9 gene 
expression was downregulated in response to stimulation with CM (Figure 5E). 
The changes that were observed in phenotype, cytokine concentrations and 
transcriptional profile of monocytes stimulated with CM, indicate that CM not 
only promoted survival of monocytes but also skew monocytes towards type 2 
macrophages.
MSC-induced and monocyte-dependent Treg formation is mediated by 
CCL18
Since CCL18 has been implicated in the generation of Tregs 22;23, we hypothesized 
that the MSC-induced CCL18 production by monocytes was involved in the MSC-
induced Treg induction that was observed in PBMC-MSC co-cultures. Indeed, 
the culture supernatant of monocytes stimulated with CM contained measurable 
concentrations of CCL18. These CCL18 concentrations were significantly higher 
than those in culture supernatant of unstimulated monocytes, which were hardly 
detectable by ELISA (detection limit of the standard curve was 0.78 pg/ml) (Figure 
7A). Since addition of an inhibitor of the TGF-β1 receptor resulted in an inhibition of 
the MSC-induced Treg formation, we also tested whether TGF-β1 was involved in 
the MSC-induced secretion of CCL18 by monocytes. Addition of a TGF-β1-receptor 
inhibitor did not reverse the increase in CCL18 secretion in monocytes induced by 
CM. Moreover, addition of recombinant TGF-β1 did not result in CCL18 secretion 
by monocytes (figure 7A), indicating that the induction of CCL18 secretion by MSC 
is not mediated by TGF-β1. 
Addition of neutralizing antibodies against CCL18 to the PBMC-CM cultures 
during the first week resulted in decreased MSC-induced Treg formation (Figure 
7B,C). These data indicate that MSC-induced CCL18 promotion by monocytes is 
responsible for the generation of Tregs. 
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Discussion
In this study, we explored the factors and cellular interactions involved in the MSC-
induced formation of CD4+CD25hiFoxP3+ Tregs derived from PBMC. We showed 
that MSC promote the generation of CD4+CD25hiFoxP3+ T cells with regulatory 
capacities, which is mediated directly by TFG-β1. In addition, this is dependent on a 
novel pathway for the MSC-induced generation of Tregs, for which the presence of 
monocytes is crucial. We showed that MSC promote monocyte survival and induce 
skewing of monocytes towards a cell type with an anti-inflammatory, macrophage 
type 2 phenotype. These cells produce IL-10 and mediate Treg formation through 
the production of CCL18. We hypothesize that both the TFG-β1 mediated pathway 
and the modulation of monocytes are essential for the MSC-induced generation 
of Tregs. 
Despite the variability in the frequency of Tregs generated by co-culture of PBMC 
with MSC that was observed between experiments, the observation that addition 
of MSC or CM resulted in a higher frequency of Tregs  was a robust finding.
Transwell experiments and the use of CM showed that the MSC-induced Treg 
formation is dependent on soluble factors secreted by MSC. In contrast to other 
reports 24;25, MSC produce these factors constitutively and do not require activation. 
It has been reported that TGF-β1 is involved in the generation and expansion of 
Tregs and it is constitutively expressed and secreted by MSC 26-28. Our finding that 
HO-1 is involved in the MSC-induced Treg formation confirms previous studies 29. 
However, since HO-1 is not a secreted factor, it plays no role in the effects reported 
in this study.
Here we confirm that in this in vitro culture system TGF-β1 is an essential factor 
involved in MSC-mediated promotion of Treg induction, indicating that TGF-β1 
produced by MSC might have a direct promoting effect on the formation of Tregs 
from T cells. 
We did not investigate whether the generated Tregs were induced from CD4+FoxP3- 
T cells or whether the natural Tregs preferentially survive or proliferate. Crop et al. 
14, however, showed that in this in vitro system the CD4+CD25hi fraction of the PBMC 
is highly proliferative during the second week of culture, indicating proliferation 
of already existing Tregs. An important finding of this study is the crucial role 
of monocytes in the MSC-induced Treg formation. Other studies showed that 
monocytes are important mediators for the immunosuppressive effect of MSC on 
T cell proliferation 30. Here we have identified an additional pathway and we show 
that the MSC-induced formation of Tregs is also mediated by monocytes, revealing 
an indirect route for MSC to promote Treg formation. The essential involvement of 
monocyte modulation for MSC-induced Treg formation in addition to the presence 
of TGF-β1 also explains why we did not observe Treg formation in co-cultures of 
purified CD4+ T cells and MSC. 
MSC promoted the survival of monocytes, which was confirmed by gene expression 
profiling of the monocytes, that showed downregulation of apoptosis-related 
genes in monocytes in response to CM. M-CSF promotes monocyte survival and 
is secreted by MSC and we showed that this factor is involved in the promotion of 
monocyte survival by CM. 
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In addition to their effect on monocyte survival, we found that MSC skew the 
differentiation of monocytes towards type 2 macrophages, similar to what has 
been suggested for fully differentiated macrophages 31. In accordance, soluble 
factors derived from MSC induce upregulation of the expression of the surface 
markers CD206 and CD163 and downregulation of expression of the co-stimulatory 
molecule CD86. This was confirmed by gene expression profiling, that showed 
increased gene expression of CD206, CD163, GAS6, PLTP and CCL18. These genes 
are associated with the immune modulating and anti-inflammatory properties of 
type 2 macrophages 32-35.
The hypothesis that MSC skew monocytes towards type 2 macrophages was 
further supported by the observed changes in cytokine concentrations.  It is 
well established that type 2 macrophages produce anti-inflammatory cytokines, 
including IL-10 and CCL18 22;32;36. Concentrations of these cytokines were 
increased in supernatants of monocytes cultured in the presence of CM and 
antibody neutralization experiments showed that monocyte-derived CCL18 
mediated the MSC-induced generation of Tregs. We previously showed that MSC 
do not produce IL-10 and that soluble factors produced by MSC induce IL-10 
production by monocytes 37. The data from the current study suggested M-CSF as 
a candidate factor for this effect. However, addition of neutralizing anti-M-CSF-R 
antibodies did not prevent IL-10 secretion by monocytes, indicating that other 
factors produced by MSC are responsible for Il-10 induction. 
Antibody neutralization experiments indicated that the increase in CCL18 
concentrations that was observed in monocyte cultures in the presence of CM 
was not dependent on TGF-β1. Since Martinez et al. showed that alternative 
stimulation of monocytes results in upregulation of CCL18 38, the role of IL-4 and 
IL-13, cytokines that induce alternative activation of monocytes 39, would be of 
interest for further research on the CCL18-inducing effect of MSC.
Interestingly, type 2 macrophages have been implicated in the formation of Treg 
in co-culture 40, which could explain the requirement for monocytes in the MSC-
induced Treg formation. Conversely, Tregs are able to induce differentiation 
of monocytes towards type 2 macrophages 41, thus creating a loop for further 
amplification of Treg production.
In conclusion we hypothesize that the MSC-induced formation of Tregs relies 
on multiple direct and indirect mechanisms (Figure 7D). MSC-derived TGF-β1 
might act directly on the T cells to promote their differentiation towards Tregs. In 
addition, the modulation of monocytes is a crucial mechanism through which MSC 
indirectly promote Treg formation. MSC promote survival of monocytes and skew 
monocyte differentiation towards modulatory type 2 macrophages that secrete 
IL-10 and that induce Treg formation through the production of CCL18. Further 
studies are required to identify MSC-derived factors that are responsible for the 
skewing of monocytes. Our results contribute to the understanding of the cellular 
networks that are involved in MSC-mediated Treg formation and show a crucial 
role for monocytes/macrophages in MSC-induced immune modulation. 
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Histograms of two different PBMC populations 
at day 14. When MSC were present during the 
first week of MSC-PBMC co-culture, a CD25+ cell 
population emerges while this is not observed when 
PBMC were cultured without MSC. No increase of 
CD69 and CD127 expression is seen on the PBMC 
after co-culture with MSC. Tinted histogram, PBMC 
alone; straight line, MSC 1; dashed line, MSC 2.
Supplemental figure 1. CD4+CD25hiFoxP3+ T cells do not express T cell activation marker CD69 and 
CD127.
Cytokine concentrations of TGF-β1 and M-CSF were measured in cell culture supernatants of 
unstimulated MSC. Both cytokines were constitutively secreted by MSC. 
Supplemental figure 2. Constitutively secreted cytokines by MSC.
Supplemental figures
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(A) Apoptosis set from Alcala et al. Oncogene 
2008: Genes involved in apoptosis are 
enriched in unstimulated monocytes (‘ctr’) 
compared to CM stimulated monocytes (‘CM’). 
Stat3 target set from Dauer et al. Oncogene 
2005: Monocytes that are stimulated with 
CM show activation of the STAT3 pathway. 
(B) unstimulated monocytes (‘ctr’) versus CM 
stimulated monocytes (‘CM’), (C) CM+M-CSF 
stimulated monocytes (‘CM+M-CSF’) versus 
M-CSF stimulated monocytes (‘M-CSF’). 
Supplemental figure 3. Gene set enrichment 
analysis of microarray data.
Supplemental figure 4. Stimulation of monocytes 
with CM results in a decrease of pro-inflammatory 
cytokine secretion by monocytes.
Cytokine concentrations were measured 
in culture supernatant from monocytes 
stimulated for 3 days with and without M-CSF 
and/or MSC-CM using the Bio-plex Pro Human 
27-plex panel. Data from cytokines that were 
decreased in supernatants of monocytes 
after stimulation with CM are represented as 
heatmap.  
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Summary and discussion
The application of MSC as therapeutic agent to treat a variety of immune related 
diseases is currently under investigation in preclinical and clinical studies. 
Although promising results have been reported, more insight in the basic MSC 
biology and in the mechanisms by which MSC modulate the immune system are 
necessary to optimize the safe and effective application of MSC in the clinic. 
This thesis describes our contributions to the understanding of the 
immunomodulatory mechanisms of MSC. We also investigated some translational 
aspects of MSC therapy, aiming at selecting the preferred tissue source for clinical 
application. 
Selecting the optimal MSC population
MSC are rare cells that are found in a variety different tissues 1. Currently, bone 
marrow is mainly used as MSC source in clinical trials. In these trials, the infused 
cell products exist of ex vivo expanded MSC populations derived from bone marrow 
mononuclear cells. Recent studies highlighted methods for prospective isolation 
of MSC with differential capacities using markers like CD146, CD271 and CD56 
2;3. Fundamental research on MSC subpopulations with specific capacities and on 
the differences between tissue sources would greatly enhance the possibilities of 
clinical application, since it may enable making a balanced choice for a specific 
MSC tissue source or subpopulation for each indication. 
The work presented in chapter 2 addresses the variation in proliferative capacity 
of MSC derived from bone marrow aspirates. We investigated the underlying 
variation in clonal bone marrow composition in this study and confirmed the 
clonal heterogeneity within MSC populations, similar to what was described by 
others 4;5. Heterogeneity in differentiation potential was observed within each MSC 
population and the frequency of clones with a specific differentiation capacity 
was different between donors. We directly related the differentiation capacity of 
clones to their expansion potential. The colonies with osteogenic differentiation 
capacity exhibited a relatively high proliferation rate and formed larger colonies. 
The experiments showed that a high variation in phenotypes is present within the 
primary MSC population and that the osteogenic lineage is most prominent, which 
is in line with current literature 4-7. We propose a hierarchical model in which colonies 
with osteogenic potential are more primitive than purely adipogenic colonies and 
in which cells gradually lose their differentiation potential, concurrently with a loss 
in proliferation rate. 
In chapter 3 we performed experiments to investigate adipose tissue as an alternative 
for bone marrow as source for MSC. Comparisons between AT-MSC and BM-MSC 
were described by others, but our study is the first to compare age-matched donor 
groups. We systematically compared the in vitro immunomodulatory capacities 
of AT-MSC and BM-MSC. We found that MSC from both sources exhibited 
immunomodulatory capacities, including their suppression of proliferation of 
stimulated PBMC and their inhibition of monocyte-to-iDC differentiation. However, 
on a per cell basis the AT-MSC proved more potent in their immunomodulatory 
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effects than BM-MSC. This was related to higher levels of cytokine secretion by AT-
MSC. Our results indicate that AT-MSC can be considered a promising alternative 
to BM-MSC for future immunomodulatory clinical applications.
Adipose tissue as a source of MSC has many advantages over bone marrow, 
including its higher frequency of MSC and its reduced donor burden associated 
with the tissue collection process, since adipose tissue, that is regarded as waste 
after liposuction, can be collected without any additional risk for the donor 8-10. 
These advantages, together with our results that showed that fewer AT-MSC were 
needed for effective immunomodulation by MSC than BM-MSC, could eventually 
lead to a higher feasibility and cost reduction of MSC therapies. 
The use of UCB-MSC has been suggested as another alternative to BM-MSC. 
UCB-MSC are thought to be more primitive than BM-MSC, resulting in high 
proliferation rates and high multilineage differentiation capacity. This would be 
interesting for the use of UCB-MSC as regenerative therapy. The disadvantage 
of UCB is, however, that it contains very low numbers of MSC. We were able to 
isolate MSC from 43% of UCB (starting with 100-150 ml blood per umbilical cord) 
that were processed (unpublished data), which is in line with what was reported 
by others 11-13. Moreover, low numbers of colonies  were generated (1 or 2 per 
sample), resulting in an expanded MSC product consisting of the outgrowth of 1 
or 2 clonal populations. This may lead to high variation in expanded UCB-MSC, 
depending on the capacities of the few clones that were isolated. However, once 
colonies were generated, UCB-MSC showed a high proliferation rate and could 
easily be expanded to a high number of cells. On a functional level, UCB-MSC have 
been reported to have similar differentiation and immunomodulatory capacities 
as BM-MSC 12;14. The low frequency of MSC in UCB limits the use of UCB-MSC for 
autologous MSC therapy, but the high proliferation frequency of UCB-MSC makes 
it an interesting tissue source for biobanking purposes. 
Factors involved in immunomodulation by MSC
MSC modulate the immune system through their interaction with a variety of 
immune cells and immunological processes. In the studies described in this thesis 
we explored the mechanisms and factors that are involved in the inhibitory effect 
of MSC on the differentiation of monocytes towards iDC and (chapter 4) and in 
their induction of Treg formation (chapter 5). 
We showed that MSC were able to inhibit the differentiation of CD14+CD1a- 
monocytes towards CD14-CD1a+ iDC. The involvement of IL-10 and IL-6 in 
immunosuppressive activities by MSC had previously been suggested by others 
15-18 and it was reported that monocyte differentiation can be inhibited by these 
cytokines 19;20. In our experiments, neutralization and cytokine-depletion strategies 
were applied to reveal the cellular source and effect of IL-6 and IL-10. We found that 
IL-10 is not produced by MSC, but exclusively by monocyte-derived cells (MDC). 
After exposure to IL-6, this IL-10 production is markedly enhanced. Neutralization 
of IL-6 diminished the inhibitory effect of MSC and almost completely blocked the 
IL-10 production by MDC. Since MSC constitutively secrete IL-6, addition of these 
cells indirectly increased the IL-10 concentration in the culture through skewing of 
monocytes towards an IL-10 producing cell population. It was reported that IL-10 
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induces the production of HLA-G by MSC 21;22, which indicates a positive feedback 
loop that could further enhance the immunomodulatory effects of MSC.
The generation of Tregs induced by MSC might be a way in which MSC can induce 
long-term immunomodulating effects. In the MSC-mediated induction of Treg 
formation (chapter 5), we demonstrated an important role for TGF-β1, similar to 
what was suggested by others 23. The formation of Tregs induced by MSC could not 
be prevented by blocking IL-6 in the culture. Furthermore we found that inhibition 
of HO-1, which was also reported to mediate the MSC-induced formation of 
Tregs 24, impaired the formation of Tregs. We concluded, however, that the effect 
of HO-1 can be taken over by other factors, since it is not secreted by MSC and 
the induction of Treg formation could be accomplished by conditioned medium 
from unstimulated MSC. We also found that MSC-derived factors induced the 
skewing of monocytes towards CCL18 producing cells with a type 2 macrophage 
phenotype and the presence of these monocytes/macrophages was crucial for the 
MSC-mediated induction of Tregs. The survival of monocytes was promoted by 
MSC, which was mediated by M-CSF. Furthermore, M-CSF was partly responsible 
for the MSC-induced skewing of monocytes towards type 2 macrophages with 
increased expression of CD206 and CD163, but not for the induction of CCL18, 
which could not be explained by the secretion of TGF-β1 by MSC. Based on our 
data we propose that the indirect route via modulation of monocytes and the direct 
route by secretion of TGF-β by MSC are essential for the induction of Tregs. The 
MSC-derived factor that is responsible for the skewing of monocytes towards 
CCL18 producing cells is as yet unknown. Others showed that CCL18 secretion 
is upregulated when monocytes are alternatively activated 25. IL-4 and IL-13 are 
putative factors that would be interesting to investigate, since these cytokines 
they could be involved in the alternative activation of monocytes 26;27. 
Several reports indicated that MSC need to be activated in order to exert their 
immunomodulatory effects 16;17;28-30. The pro-inflammatory cytokines IFN-γ and 
TNF-α were effectively used to enhance the inhibitory effects of MSC 30;31. IFN-γ 
induces the expression of IDO and it increases the secretion of PGE2, that are both 
implicated as important mediators of immunomodulation by MSC 32;33. In chapter 4 
and 5, we showed that conditioned medium from unstimulated MSC was sufficient 
to inhibit monocyte differentiation towards iDC, to promote the formation of Tregs 
and to skew monocytes towards macrophage type 2 cells. This indicated that, in 
order to exert these immunomodulatory effects, MSC-activation is not required. We 
demonstrated that the production of the IL-6 protein by MSC, the effector cytokine 
for the inhibition of monocytes differentiation towards iDC, was not altered after 
interaction of MSC with monocytes and/or IL-4 and GM-CSF. However, IL-4 and 
GM-CSF increased the mRNA levels of IL-6 expressed by MSC, suggesting that 
activation of MSC might enhance their immunomodulatory effects. 
Our observations that activation may not be required for all immunomodulatory 
effects of MSC fits with the model that was proposed by Singer and Caplan 17. 
This model differentiates between IFN-γ-dependent and –independent pathways 
of immunomodulation by MSC. In an inflammatory environment, activated T cells 
produce IFN-γ and this induces the production of IDO, which inhibits the proliferation 
of effector T cells. Independent of IFN-γ, MSC constitutively secrete cytokines like 
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TGF-β, IL-6 and PGE2, which are all involved in the immunomodulatory effects 
of MSC. Our in vitro culture systems of monocyte-to-iDC differentiation and Treg 
formation lack activated T cells and no IFN-γ is present in the system. Therefore, 
MSC were not activated in these cultures and we hypothesize that the constitutive 
secretion of cytokines by MSC was sufficient for the immunomodulatory effects 
we observed.  
In chapter 3 we studied the MSC-mediated suppression of PBMC proliferation. 
In this system IFN-γ is produced and this resulted in an increase of IDO mRNA, 
corresponding to the current literature 33;34. It is conceivable that in such an 
inflammatory environment, MSC respond by altering their secretion profile, 
initiating and enhancing their immunomodulatory effects. 
Central role for monocytes in immunomodulation by MSC
Monocytes are major players of the innate immune response as regulators of 
inflammation. Monocytes (mostly CD14+CD16-) 35 circulate in the blood and can 
migrate into the tissue under inflammatory conditions, where they differentiate 
towards macrophages or DC 36. Different types of macrophages exist with distinct 
biological functions. The best described macrophage is the type 1 macrophage 
(classically activated macrophage) that, activated by IFN-γ and TNF-α, becomes 
an effector cell that produces pro-inflammatory cytokines and is able to kill 
and degrade microorganisms. Type 2 macrophages (alternatively activated) 
on the other hand, are a tolerogenic cell type with an anti-inflammatory role. 
Type 2 macrophages are activated by various stimuli, including IL-4, IL-13, 
immune complexes or prostaglandins  27;37;38. The latter type of macrophages 
can be subdivided in macrophages that play a role in tissue repair and regulatory 
macrophages with anti-inflammatory activity. Regulatory macrophages upregulate 
mannose receptors (CD206) 39 and secrete high levels of the anti-inflammatory 
cytokines IL-10 and low levels of IL-12 27;37;38. The phenotype of macrophages can 
change over time due to response to environmental signals. Therefore, Mosser 
proposed that a spectrum of different shades of activation exists based on 
macrophage function 38.
An important finding from the work that is presented in this thesis is the major role 
for monocytes as mediators of the MSC induced immunomodulation. We showed 
that MSC regulate monocyte differentiation by preventing the differentiation to 
antigen presenting DC and promoting skewing of monocyte differentiation towards 
IL-10 producing cells with an impaired ability to stimulate allogeneic T cells. We 
demonstrated that MSC promote monocyte survival and their skewing towards 
macrophage type 2 cells, similar as has been suggested by others 31;40. This effect 
was partly regulated by M-CSF, which is produced  by MSC. We showed that 
MSC induce monocytes to acquire a phenotype that is in accordance to what is 
described for type 2 macrophages, including upregulation of the surface markers 
CD206 and CD163, upregulation of PLTP, GAS6 and CCL18 expression and high 
secretion of IL-10 and low secretion of IL-12. These type 2 macrophage-like cells 
secrete CCL18, that proved to be responsible for induction of Treg formation.
The importance of monocytes was already described for the MSC-mediated 
suppression of T cell proliferation 29;41-43. Here we show, that also for the MSC-
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mediated induction of Treg formation, the presence of monocytes is crucial. We 
hypothesize that the MSC-induced skewing of monocytes towards regulatory, 
anti-inflammatory cells is an essential part of the modulation of the immune 
response by MSC (figure 1).  
Figure 1. hypothetical model of direct and indirect routes of immunomodulation by MSC.
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Future perspectives 
This thesis supports the role of MSC as powerful modulators of the innate and 
adaptive immune response. Immune suppression by MSC through modulation of 
monocytes and macrophages sheds a new light on the possible mechanism of 
therapeutic application of MSC for immunomodulatory purposes. The involvement 
of type 2 macrophages in tissue repair might link the immunomodulatory properties 
of MSC to the possibly advantageous effects of MSC for tissue regeneration. 
Monocyte modulation might also clarify the observed systemic effects of MSC, 
despite local entrapment in the lungs after intravenous administration. Systemic 
effects might be the result of the secretion of immunomodulating factors by MSC 
that induce skewing of monocytes, that circulate throughout the body, towards 
anti-inflammatory macrophages. It would be of interest to investigate whether, in 
certain conditions, administration of MSC conditioned medium or MSC-‘educated’ 
monocytes might be efficient in exerting the desired immunomodulatory effect.
It is still unclear whether the in vitro observed MSC effects are of functional biological 
relevance in vivo. Therefore, it is important to develop relevant preclinical models to 
investigate MSC therapy and the underlying mechanisms of immunomodulation. 
In addition, translational issues should be investigated, like ‘what is the optimal 
time and dose of MSC infusion?’, ‘should MSC be infused locally or systemically?’ 
and ‘do MSC need to be activated ex vivo or in vivo after infusion?’. 
In conclusion, the fundamental studies presented in this thesis on the 
immunomodulatory effects of MSC may provide valuable knowledge on how to 
proceed with applying MSC as a therapy in immune related diseases. 
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Multipotente stromale cellen (MSC) zijn als eerste geïdentificeerd in het beenmerg 
in de jaren ’60 van de vorige eeuw. Na het in kweek brengen van beenmerg in het 
laboratorium, worden MSC gekarakteriseerd door hun vermogen om te plakken 
aan plastic en de capaciteit om uit te rijpen (differentiëren) tot de verschillende 
mesenchymale weefsels, namelijk bot-, vet- en kraakbeencellen. De International 
Society for Cellular Therapy (ISCT) heeft de minimale criteria omschreven waaraan 
een cel moet voldoen om als MSC geïdentificeerd te worden. Deze criteria zijn: 
1) de capaciteit om te differentiëren in de richting van bot, vet en kraakbeen en 
2) de aanwezigheid of afwezigheid van een bepaalde combinatie van eiwitten op 
het oppervlak van de cel waarmee MSC zich onderscheiden van andere celtypen. 
Naast de capaciteit van MSC om te differentiëren naar bot, vet en kraakbeen, 
kunnen ze ook ontstekingsreacties onderdrukken. Deze functie van MSC als 
onderdrukkers van het immuunsysteem maakt het interessant om te onderzoeken 
of MSC gebruikt kunnen worden voor de behandeling van immuun-gerelateerde 
ziektes, zoals Graft-versus-host ziekte (de afweerreactie die kan ontstaan na een 
beenmergtransplantatie, waarbij het donorbeenmerg, de ‘graft’, de ontvanger, 
de ‘host’, aanvalt), auto-immuunziekten en ontstekingsziekten als de ziekte van 
Crohn. 
Het immuunsysteem bestaat uit verschillende soorten cellen (witte bloedcellen) 
die elk verschillende functies hebben. Belangrijk voor de acute afweerrespons 
en de het eerste verdedigingsmechanisme van het immuunsysteem zijn de 
monocyten. Monocyten kunnen uitrijpen tot dendritische cellen, die behoren tot 
de antigeen-presenterende cellen of, als ze het bloed verlaten om in het weefsel 
actief te worden, tot macrofagen. Als er ergens een ontsteking is, verplaatsen 
monocyten zich razendsnel via de bloedcirculatie naar deze ontsteking. Hier 
verlaten ze de bloedstroom en differentiëren tot macrofagen. Macrofagen kunnen 
op de ontstoken plek lichaamsvreemde micro-organismen of aangetaste cellen 
verwijderen. Van macrofagen zijn meerdere subtypes te onderscheiden, afhankelijk 
van de manier waarop ze geactiveerd worden. M1-macrofagen produceren veel 
ontstekingsstoffen om het lichaam te verdedigen tegen ziekteverwekkers, maar 
richten daarbij ook schade aan het omliggende weefsel aan. M2-macrofagen zijn 
meer gespecialiseerd in herstel van weefselschade en de onderdrukking van de 
immuunrespons. 
Naast de acute immuunrespons, is er ook de adaptieve immuunrespons. Belangrijk 
hiervoor zijn de T cellen, die zorgen voor de specifieke cellulaire afweerrespons. 
Deze respons ontstaat als T cellen een molecuul herkennen dat gepresenteerd 
wordt door een antigeen-presenterende cel. Antigeen-presenterende cellen kunnen 
een gedeelte van een lichaamsvreemd molecuul (afkomstig van bijvoorbeeld een 
bacterie, virus of een lichaamsvreemde cel), ofwel een antigeen, op hun oppervlak 
brengen, waarna dat herkend kan worden door de T cel. Pas als de T cel het 
antigeen herkent, kan de cellulaire afweerreactie in gang gezet worden, waarbij 
allerlei stoffen worden uitgescheiden door de T cel waarmee de vreemde cel wordt 
vernietigd. Er zijn echter ook regulatoire T cellen (Tregs), die de balans van de 
afweerreactie in de gaten houden en de sterkte van een immuunrespons kunnen 
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afremmen. 
We weten dat MSC interacties aan kunnen gaan met al deze verschillende cellen 
van het immuunsysteem en op die manier de immuunrespons kunnen beïnvloeden. 
MSC worden nu al getest en succesvol toegepast om de afstotingsreacties, die 
kunnen optreden na een beenmerg transplantatie, te onderdrukken. Ook voor de 
behandeling van ontstekingsziekten als de ziekte van Crohn wordt het toedienen 
van MSC onderzocht. Wat MSC precies doen in het lichaam na infusie is nog niet 
helemaal duidelijk. Om patiënten op de juiste manier te kunnen behandelen is het 
belangrijk dat we meer inzicht krijgen in de interacties en de stoffen die belangrijk 
zijn voor de werking van MSC. In dit proefschrift is onderzocht wat voor effect 
MSC precies hebben op T cellen, Tregs, dendritische cellen en monocyten en welke 
stoffen en mechanismen hierbij belangrijk zijn. 
De eerste MSC cellen die gaan groeien na het in kweek brengen van beenmerg, 
vormen kolonies van cellen en aangenomen wordt dat alle cellen in zo’n kolonie 
afkomstig zijn uit dezelfde voorlopercel. Tussen de kolonies zitten verschillen in 
groeisnelheid en de capaciteit tot differentiatie, sommigen zijn bijvoorbeeld alleen 
in staat te differentiëren naar bot, terwijl andere kolonies het vermogen hebben 
om te differentiëren naar zowel bot, vet en kraakbeen. Na een periode van kweek 
(expansie) buiten de patiënt (ex vivo) vormen de cellen, afkomstig uit verschillende 
kolonies, een populatie die een zeer gemengde samenstelling heeft van cellen 
met verschillende capaciteiten tot differentiatie en groeisnelheid. Er is nog weinig 
bekend over hoe MSC er precies uitzien als ze in het lichaam zitten en dus welke 
cellen er aan de basis staan van een cel populatie na een aantal weken kweek. Als 
we erachter kunnen komen hoe we MSC kolonies met een bepaalde groeisnelheid 
of differentiatiecapaciteit al heel vroeg kunnen identificeren, zou dit de mogelijkheid 
geven om een cel populatie te kweken die beter toegespitst is op een bepaalde 
klinische toepassing, bijvoorbeeld een populatie die heel goed naar bot kan 
differentiëren voor toepassing als celtherapie voor botreparatie na botbreuken. De 
studie die wordt beschreven in hoofdstuk 2 van dit proefschrift had als doel om 
de verschillende typen kolonies waarmee een MSC kweek uit beenmerg begint te 
onderzoeken. We hebben gekeken naar de differentiatiecapaciteit en groeisnelheid 
van primaire kolonies en de cellen die hier uit voort komen. De MSC met de 
capaciteit om naar bot te differentiëren hadden een hogere groeisnelheid dan de 
cellen die naar vet differentiëren en andersom hadden de cellen die geselecteerd 
werden voor een hoge groeisnelheid een betere differentiatie capaciteit in de 
richting van bot dan cellen met een lage groeisnelheid. Wij concluderen dat MSC 
kolonies met de capaciteit om naar bot te differentiëren primitiever zijn dan de 
cellen die naar vet differentiëren. 
MSC werden als eerste geïdentificeerd in beenmerg, en dat is ook de bron die tot op 
heden het meeste gebruikt wordt voor klinische studies. Daarnaast worden MSC 
ook verkregen uit andere weefsels en organen, zoals vet, huid, nier, long, placenta, 
navelstreng en navelstrengbloed. De efficiëntie om MSC te isoleren uit verschillende 
weefsels is onderzocht en hieruit bleek het in alle gevallen mogelijk om MSC te 
isoleren uit beenmerg en vet, terwijl maar 63% van de navelstrengbloed monsters 
MSC opleverde. Als er MSC geïsoleerd konden worden uit navelstrengbloed hadden 
deze cellen wel een hogere groeisnelheid vergeleken met MSC die geïsoleerd waren 
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uit beenmerg of vet. Voor de klinische toepassing van MSC is vet een aantrekkelijke 
bron, omdat vet een relatief hoog aantal MSC bevat en in de huidige praktijk wordt 
vet gezien als ‘rest-weefsel’ na liposuctie ingrepen, waardoor het makkelijk te 
verkrijgen is. In hoofdstuk 3 hebben we een systematische vergelijking gedaan 
van beenmerg en vet als bron voor MSC. Hiervoor werden MSC gebruikt die waren 
geïsoleerd uit beenmerg en uit vet van twee groepen met gelijke leeftijd. We hebben 
gekeken naar de capaciteit van MSC om het immuunsysteem te onderdrukken. 
MSC van beide bronnen bleken goed in staat om de deling en activiteit van T 
cellen te onderdrukken. Daarnaast konden beide typen MSC de differentiatie van 
monocyten naar dendritische cellen remmen. We vonden ook een verschil tussen 
de MSC uit beenmerg en uit vet, namelijk dat MSC die geïsoleerd waren uit vet 
een veel sterker remmend effect op T cellen en dendritische cellen lieten zien dan 
MSC uit beenmerg. Met andere woorden; om hetzelfde effect te bereiken waren 
minder vet-MSC nodig dan beenmerg-MSC. Deze potentere activiteit van vet-
MSC was waarschijnlijk het resultaat van een hogere metabole activiteit. Ook 
de uitscheiding van de stoffen die verantwoordelijk zijn voor de onderdrukking 
van het immuunsysteem (immunomodulerende factoren) was hoger in vet-MSC 
vergeleken met beenmerg-MSC. 
In hoofdstuk 4 en hoofdstuk 5 zijn we dieper ingegaan op de mechanismen 
die belangrijk zijn voor de immunomodulerende werking van MSC. We hebben 
onderzocht welke stoffen (cytokinen) belangrijk zijn voor de remming van de 
differentiatie van monocyten naar dendritische cellen onder invloed van MSC 
(hoofdstuk 4). De cytokinen IL-6 en IL-10 bleken betrokken bij dit proces en alleen 
IL-6 werd ook daadwerkelijk geproduceerd en uitgescheiden door MSC. IL-10 (een 
ontstekingsremmend cytokine) werd alleen geproduceerd door de monocyten en 
dit was sterk verhoogd na stimulatie van monocyten met MSC. Deze verhoging 
van IL-10 productie door monocyten was afhankelijk van de IL-6 die door de MSC 
werd uitgescheiden. De IL-10 producerende cellen, die ontstonden na differentiatie 
van monocyten naar dendritische cellen in de aanwezigheid van MSC, bleken 
veel minder goed in de activatie van T cellen dan dendritische cellen die waren 
ontstaan in de afwezigheid van MSC. MSC remmen dus niet alleen de differentiatie 
van monocyten naar dendritische cellen maar veroorzaken tegelijkertijd de 
differentiatie van monocyten naar IL-10 producerende cellen die een dempende 
werking hebben op het immuunsysteem.   
Het stimuleren van de vorming van Tregs, die een dempende werking hebben op 
de afweerreactie, is een andere manier waarop MSC een modulerende werking 
zouden kunnen hebben op de immuunrespons. In hoofdstuk 5 hebben we gekeken 
naar de vorming van Tregs onder invloed van MSC. We concluderen dat het eiwit 
TGF-β, uitgescheiden door MSC, een belangrijke rol speelt in dit proces. In deze 
experimenten waren behalve T cellen ook monocyten aanwezig en deze bleken 
belangrijk te zijn voor de MSC-geïnduceerde vorming van Tregs. Onder invloed van 
MSC werd de productie van CCL18 door monocyten verhoogd en de aanwezigheid 
van deze CCL18-producerende monocyten bleek essentieel voor de vorming van 
Tregs in de kweek. Nadere bestudering van de monocyten liet zien dat monocyten 
onder invloed van MSC differentieerden naar M2-macrofagen.
De cruciale rol van monocyten voor de verschillende immunomodulerende 
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activiteiten van MSC is een belangrijk resultaat van de studies die staan beschreven 
in dit proefschrift. Het was al bekend dat voor de remming van T cel deling en 
activatie de aanwezigheid van monocyten belangrijk is en hier laten we zien dat 
ook voor de MSC-geïnduceerde vorming van Tregs monocyten van essentieel 
belang zijn. Onze hypothese is dat MSC monocyten stimuleren tot de vorming van 
regulatoire, ontstekingsremmende cellen en dat deze MSC-monocyten interactie 
een essentieel onderdeel is van de modulatie van de immuunrespons door MSC. 
De betrokkenheid van monocyten bij het therapeutische effect van MSC zou een 
verklaring kunnen zijn voor het systemische effect (in het hele lichaam) dat MSC 
kunnen hebben, terwijl MSC na toediening veelal in de longen blijven hangen. 
Het is niet ondenkbaar dat MSC in de longen bepaalde stoffen uitscheiden 
die effect hebben op de monocyten in de bloedcirculatie en op die manier hun 
invloed uitoefenen. Om dit mechanisme verder te ontrafelen is verder onderzoek 
noodzakelijk. 
De studies beschreven in dit proefschrift zijn allemaal uitgevoerd in vitro (in een 
kweekschaaltje) en het is nog niet duidelijk hoe relevant deze resultaten zijn voor 
wat er daadwerkelijk in vivo (in het lichaam) gebeurt. Om dit te onderzoeken is 
het belangrijk dat er preklinische (dier)modellen ontwikkeld worden om MSC 
therapie en de onderliggende mechanismen te onderzoeken. Daarnaast moeten 
er translationele vragen beantwoordt worden over het optimale tijdstip en de 
dosis van MSC toediening en of ze lokaal of systemisch zouden moeten worden 
toegediend. 
De fundamentele studies naar de immunomodulerende effecten van MSC die 
beschreven staan in dit proefschrift leveren waardevolle kennis op voor verder 
onderzoek naar de toepassing van MSC als therapie voor immuungerelateerde 
ziekten. 
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